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ABSTRACT OF THE DISSERTATION
RANDOMIZED CLINICAL TRIAL OF THE EFFECT OF ORAL
SUPPLEMENTATION WITH N-ACETYL CYSTEINE AND GLYCINE ON
BIOMARKERS OF OXIDATIVE STRESS AND INFLAMMATION IN PEOPLE
LIVING WITH HIV (PLWH) FROM THE MASH COHORT
by
Alhanoof Al-Ohaly
Florida International University, 2020
Miami, Florida
Professor Adriana Campa, Major Professor
HIV infection has been associated with glutathione (GSH) depletion, oxidatively
damaged DNA, and inflammation. People living with HIV (PLWH) have subnormal
levels of GSH and elevated levels of inflammation biomarkers such as C-Reactive
Protein (CRP). Failure of the antioxidant enzymatic system increases oxidatively
damaged DNA. The objective of this double-blinded randomized clinical trial was to
supplement PLWH with a combination of N-acetylcysteine, a powerful antioxidant, and
glycine, a precursor of GSH or placebo for three months to decrease oxidative stress and
inflammation.
The trial recruited 30 PLWH from the Miami Adult Studies on HIV (MASH)
cohort at the FIU Research clinic in the Borinquen Health Center, Miami-Dade, Florida.
Participants were on stable ART, have undetectable HIV viral load, CD4 count ≥500
cells/µL, <65 years old, BMI ≤30 kg/m 2, and free of co-morbid diseases. Cocaine was
used by 50% of the participants and cocaine users were equally distributed between the
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intervention and placebo groups. We collected anthropometric measurements, pill count,
CRP, demographics, and blood samples. The alkaline and enzyme modified comet assay
was performed in whole blood to assess levels of oxidatively damaged DNA (SB/ALS,
SB/ALS + oxidized purines, and oxidized purines only), and GSH was assessed using the
Arbor Assay Glutathione Colorimetric. Supplementation significantly reduced levels of
AS/ALS + oxidized purines (p=0.005) and SB/ALS (p=0.05). There was a direct
correlation between BMI and SB/ALS (r= 0.585, p=0.009). Pill adherence was
significantly associated with supplementation (β= 0.591, p=0.001), 75% in the
intervention group were adherent. Oxidized glutathione (GSSG) decreased after
supplementation, yet did not reach significance. Post-supplementation CRP significantly
decreased among male gender (p=0.011), and was associated with decreased % body fat
(p=0.022), BMI (p=0.004), and GSSG (p=0.019). Cocaine use was associated with lower
CD4 cell counts (p=0.045) at baseline. Supplementing was effective in reducing levels of
oxidatively damaged DNA and biomarkers of inflammation, and it also decreased body
fat % and GSSG among PLWH from the MASH cohort.
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CHAPTER I: INTRODUCTION
Statement of Problem
Worldwide, HIV remains one of the world’s major public health concern, with
nearly 37.9 million people living with HIV (PLWH) at the end of 2018, with
approximately 1.7 million new infections in the same year.1,2 In the United States, 37,832
people were diagnosed with HIV in 2018, which suggested decline in new infections;
however, there are approximately 1.1 million PLWH.3 In Miami-Dade, Florida, where
this study was conducted, there are more than 27,908 PLWH.4 Miami-Dade county has
one of the highest HIV incidence and prevalence rates in the United States.3 The number
of people living with HIV/AIDS in Miami-Dade County has increased by 23% from 2004
to 2014.5 Thus, the HIV pandemic is a pressing problem in our community.
The human immunodeficiency virus (HIV) is a retrovirus that destroys and
impairs the function of the immune cells.6 Since 1996, in the era of antiretroviral therapy
(ART),7 HIV has become a chronic and manageable disease, if patients strictly adhere8 to
ART more than 80 to 95% of the time and attend their healthcare visits.9 Despite stable
ART, however, inflammation and immune activation have become major challenges for
those infected with the disease with adverse consequences for HIV progression, comorbid cardiovascular disease, and mortality.10,11,12
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Significance of Study
During infectious diseases, antioxidant and anti-inflammatory activities are vital
for controlling inflammation and oxidative stress.13 HIV presents change in the
components of the antioxidant defense system, resulting in Glutathione (GSH) depletion
which may lead to DNA damage. 14 Studies have shown that HIV results in increased
oxidative stress. 15,16,17 Increased oxidative stress generates free radicals, which then can
damage the cell and produce excessive inflammation biomarkers. The literature is limited
in considering all these aspects among PLWH. Besides, novel biomarkers are needed to
advance research in this area.
Innovation
This is the first study to apply the alkaline-hoGG1-modified comet assay to HIV
blood samples.
Aims and Hypotheses:
Primary Aim: To assess the effectiveness of three-month oral supplementation of
N-acetyl cysteine and glycine on plasma GSH concentrations, DNA damage, and
biomarkers of inflammation in HIV-infected individuals from the MASH cohort, on
stable ART, with controlled viral load. We conducted a double blinded randomized
clinical trial of 3-month supplementation.
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Hypotheses:
Hypothesis 1: Supplementation with N-acetyl cysteine and glycine in adult
PLWH on stable ART with controlled viral load will decrease the ratio of plasma
reduced GSH levels to free glutathione.
Hypothesis 2: Supplementation with N-acetyl cysteine and glycine in PLWH
on stable ART with controlled viral load will lower inflammation as measured with
plasma hsCRP.
Hypothesis 3: Supplementation with N-acetyl cysteine and glycine in PLWH
on stable ART with controlled viral load will result in lower DNA damage.
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Table 1: Statistical Analysis of Hypotheses
Hypothesis
1a: Supplementation
with N-acetyl cysteine
and glycine in adult
PLWH on stable
ART with controlled
viral load will
decrease the ratio of
plasma reduced GSH
levels to free
glutathione.
1b: Supplementation
with N-acetyl cysteine
and glycine in PLWH
on stable ART with
controlled viral load
will result in lower
DNA damage.

Independent and
Dependent
Variables
Independent:
Supplementation
with NAC and
glycine
Dependent:
Levels of reduced
glutathione
Independent:
Supplementation
with NAC and
glycine
Dependent:
Oxidatively DNA
damage

Outcomes

Controlled
Variables

Statistical
Analyses

Monthly
proportion of
people increasing
reduced
glutathione in
each group

Age, Gender
BMI at baseline,
Fat mass,
CD4 cell count
at baseline
Alcohol and
drug use at
baseline and
over time

Primary analysis:
Intent-to-treat.

Monthly
proportion of
people with
reduced markers
of inflammation
in each group

Age, Gender
BMI at baseline,
Fat mass,
CD4 cell count
at baseline
Alcohol and
drug use at
baseline and
over time

Linear Regression
was performed to
assess the
relationship
between
supplementation
and GSH.
Primary Analysis:
Intent-to-treat.
Logistic
Regression was
performed to
assess the
relationship
between
supplementation
and DNA damage
-

1c:Supplementation
with N-acetyl cysteine
and glycine in PLWH
on stable ART with
controlled viral load
will lower
inflammation as
measured with
plasma hsCRP

Independent:
Supplementation
with NAC and
glycine
Dependent:
hsCRP

Monthly
proportion of
people with
adverse events
and types of
adverse events in
each group.
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Age, Gender
BMI at baseline,
Fat mass,
CD4 cell count
at baseline
Alcohol and
drug use at
baseline and
over time

Primary Analysis:
Intent-to-treat.
Linear Regression
was performed to
assess the
relationship
between
supplementation
and inflammation
measured by
hsCRP
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CHAPTER II: LITERATURE REVIEW
HIV and Oxidative Stress
HIV contributes to increased oxidative stress in several manners.1 Oxidative
damage occurs when the production of Reactive Oxygen Species (ROS) exceeds the
capacity of antioxidant defenses to neutralize them.2 Oxidative stress damages lipids,
proteins and DNA,3 and measurements biomarkers of this damage can be used to
determine the extent of targeted and systemic oxidative stress.4 To protect tissues and
organs against oxidative stress, the body possesses external and internal antioxidant
defenses, including glutathione (GSH) and its associated enzymes.5
HIV in Miami-Dade
HIV infection leads to increased oxidative stress, which may in turn lead to faster
development of HIV-related chronic diseases.1,6 Hence, antioxidants might have a
significant adjuvant role in the treatment of HIV/AIDS.6Error! Bookmark not defined. The Miami
Adult Studies on HIV (MASH) cohort is recruiting 1,500 participants, half of whom are
people living with HIV (PLWH). Miami-Dade County currently has approximately
27,908 PLWH7 and a concentrated and growing HIV epidemic, which makes the
development of interventions to improve their quality of life, prevent and treat comorbidities and delay mortality are goals for this population.
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Glutathione and its Amino Acid Precursors
Glutathione (GSH) is a tri-peptide (L-γ-glutamyl-L-cysteinylglycine) with
numerous biological roles such as safeguarding against reactive nitrogen species (RNS)
and ROS. 8 Glutathione is the greatest copious low molecular weight thiol compound that
is created in the cells,9 which is crucial in safeguarding cells from oxidative destruction,
as well as xenobiotic electrophiles toxicity, and sustaining redox homeostasis.
Glycine (Gly), cysteine (Cys), and glutamate (Glu) are the amino acid precursors
needed to synthesize GSH.10 They are typically categorized as nonessential amino acids;
nevertheless, in some cases, the ability to synthesize GSH can be inadequate.11,12 Amino
acids are either essential, non-essential, or conditionally essential.12 The essential amino
acids are driven from the diet and the non-essential are synthesized in the body. However,
some of the non-essential amino acid become conditionally essential, to be consumed
through diet in the presence of some illnesses. Under metabolic pressure, only glutamate
and serine may remain non-essential. The conditionally essential amino acids include
cysteine, arginine, glycine, tyrosine, glutamine, and proline.
Amino acids are important to maintain good health through their actions in
several systems. Some of the important roles for the non-essential amino acids are DNA
synthesis, gene expression, immunity, and contribution to the antioxidant defense
system.13
Glutathione and its precursor, GSH are produced and have antioxidant functions
in several body systems, which includes the gastrointestinal, immune and cardiovascular
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systems. Therefore, when we have impaired GSH synthesis, its precursors become
conditionally essential to maintain the health of the individuals.
Currently, supplementation with GSH precursors has been found to decrease
infection rates.11 These precursors can assist in protecting against oxidatively generated
damage emanating from radiotherapy.
The function of the immune system is optimal when lymphoid cells contain
glutathione that is well-adjusted at the intermediate level.14 Even minute changes in the
intracellular levels of glutathione have significant impact on the functions of
lymphocytes. Some functions, like synthetic response of DNA, are very sensitive to
intermediates of reactive oxygen and are thus favored by high degrees of antioxidant
glutathione. Placebo-controlled, randomized experiments demonstrate that treating
patients infected with HIV with N-acetylcysteine resulted in a considerable rise in all
immunological functions including natural killer cell activity restoration.
Reactive oxygen species, Oxidative Stress, and Antioxidants:
Reactive oxygen species (ROS) includes those molecules that contains free
radicals and non-radicals based on their oxidizing capacity and reactivity.15 ROS are
produced via various chemical reactions with biomolecules resulting in oxidative stress.
Antioxidants are used in protecting biomolecules from the damaging impact that may be
caused by ROS. Previously, research on antioxidants largely sought to understand
ROS/free radical reactions with antioxidants employing kinetic methods and biochemical.
However, current studies also consider the capacity of antioxidants in modulating cellular
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signaling proteins, including transcription factors, secondary messengers and receptors
among others. Currently, it is evident that antioxidants are critical for human health
conditioning in their bioavailability and dosage.
Typical human biochemical reactions, higher degrees of dietary xenobiotics and
increased exposure to the environmental pollutants lead to the production of reactive
nitrogen species (RNS) and reactive oxygen species (ROS). RNS along with ROS
generate oxidative stress in various pathophysiological environments.16
Oxidative stress is also linked to aging; however, causal mechanisms are not fully
understood. Sekhar et al17 explored if glutathione deficiency occurs as a result of
decreased synthesis and facilitates oxidative stress in aging. The researchers also
explored whether stimulation of glutathione synthesis using its precursors glycine and
cysteine can decrease oxidative stress. The study found that in ageing humans,
glutathione deficiency develops due to a significant decrease in production.
Supplementing the diet with the glutathione precursors glycine and cysteine results in
restoration of glutathione concentration and synthesis, while lowering oxidative stress
levels and oxidatively generated damage.17
The mechanisms that form the basis of clinical and therapeutic application of NAcetyl Cysteine (NAC) are complicated and remain unclear. Samuni et al.18 explored the
chemistry of NAC and the manner in which it interacts and functions at the cellular,
tissue and organ level with the aim of bridging the gap between its chemistry and
recognized biological activities.18 The study conclude that NAC has an antioxidant
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activity because of its rapid reactions with CO3, NO2, OH and thiyl radicals. NAC is seen
to be unique for its effect decrease of disulfide bonds in proteins; therefore, changing the
structure and disturbing ligand bonding.
Chronic inflammation is associated with many human diseases. This response
does not demonstrate any advantages for human health that are condition specific. A diet
characterized by antioxidant products is an approach and an emergent trend for dealing
with chronic diseases’ inflammatory responses, as well as their associated risk factors.19
Lu and Yen19 reviewed the possible molecular signaling of antioxidants, along with the
anti-inflammatory impacts of specific dietary phytochemicals from common food. The
review sought to support health implications and define the understanding of the
researchers on natural bioactive substances with anti-inflammatory and antioxidant
characteristics.
La Rowe et al.,20through a “double blind placebo-controlled crossover Phase 1
trial” sought to measure the tolerability and safety of NAC in healthy cocaine users.
Since that the resultant side-effects were mild, they established that NAC was harmless
and well-tolerated among healthy individuals using cocaine.20 Ultimately, the authors
suggest that NAC aids to decrease symptoms linked to cocaine withdrawal.
Oxidative stress, DNA damage and the Application of the Comet Assay to
Measure DNA Damage:
Oxidative stress is the imbalance between antioxidants and free radicals in the
body.21 Damaged DNA is a chief consequence of oxidative stress. Deoxyribonucleic acid,
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a self-replicating material found in almost all living creatures is the core component of
chromosomes. When damaged, the DNA causes structural modifications, such as
alterations or breakage of its strand, DNA damage can happen naturally or through
environmental factors.22 The damage can alter the coding properties as well as interfere
with cell processes. As Collins et al.23 highlights, disruption in the normal redox state of
cells, on the other hand, can cause harmful effects by forming free radical peroxides that
harm the constituents of the cell, including, DNA, proteins, and lipids.23 Oxidative stress
due to oxidative metabolism not only breaks DNA strands but also damages DNA bases.
Biomarkers are essential in the evaluation of oxidative stress and the antioxidant
defense system. According to Hashimoto et al.,24 oxidative stress markers that represent
the damage due to oxidation are grouped into three categories.24First are antioxidants,
which represent the systems that handle and decrease oxidative stress. Second are
quantification of reactive oxygen species (ROS), which may be found at the cellular
level. Third are markers of oxidative damage caused in RNA/DNA, lipids and proteins.
Furthermore, DNA damage is considered one of the most common biomarker to measure
oxidative stress.25
Oxidative stress among PLWH is higher than in the general population due to the
chronic infection and treatment, which may have more than one pathway leading to DNA
damage. 26 The increased levels of DNA bases destroyed in HIV-infected people rises the
chance to develop Acquired Immune Deficiency syndrome (AIDS).27 Commonly used
tools to measure oxidative DNA damage are PCR-based assays, comet assays, and mass
spectrometry-based approaches. Comet assay is a procedure that measures DNA damage
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in an individual cell.4,24,29 The alkaline comet assay is the method of choice for measuring
different kinds of DNA damage in cells. It is a gel electrophoresis-based technique,
which is sensitive, versatile, and relatively simple to perform. The procedure is a result of
the appearance of damaged and undamaged DNA, resembling a comet. Most researchers
employ comet’s skill to detect DNA single-strand breaks.
Uses of comet assay range from sentinel bio monitoring to DNA damage
measurement in exact genomic sequences.28 The comet assay – modified-enzyme
alkaline comet assay allows the cellular proteins to detach from the cell through lysing,
after which the DNA can unwind under basic conditions.
Unrepaired DNA injuries can cause genetic variability, which accelerates cancer
growth.5 Recognizing the possible causes of DNA destruction is crucial for maintaining
the well-being of HIV people. The in vivo, alkaline comet assay senses DNA destruction.
Besides, the procedure requires small amounts of cells.
Briefly, the comet assay is a single cell-gel electrophoresis, measuring different
types of DNA damage in cells.8 Conducting the comet assay takes between two and three
days, excluding scoring of the comet assay slides. The assay includes lysis overnight,
electrophoresis and neutralization, staining and then scoring under the microscope. In
2016, it was established that the comet assay can be carried effectively with a shorter
duration of two days.29
Previously, the comet assay occupied a large bench space and the microscope
slides were placed in a horizontal sequence with a potential to damage the slides, but

13

Karbaschi and Cooke8 changed the procedure after founding that shape and orientation of
comets run straight up in the high throughput rack and were similar with the ones that
were run horizontally, with no considerable variation in proportion of tail DNA in the
vertical and horizontal samples. The study also discovered that electrophoresis can be
effectively carried out, to ensure the size and shape of the comets is not affected, with the
slides in a vertical position, instead of a horizontal position.
Glutathione Supplementation in PLWH
Glutathione (GSH) is an abundant intracellular antioxidant and it is synthesized
from its precursor amino acids: glycine, cysteine, and glutamic acid30,31,32,33 Decreased
availability of these amino acids leads to GSH deficiency, which is frequently observed
in HIV 15,34,35 In agreement with this, Sekhar et al.33 concluded that one of the causes of
GSH deficiency is diminished GSH synthesis, which is caused by decreased availability
of its precursor amino acids. In addition, several studies suggest that excessive production
of proinflammatory cytokines including TNF- !, which generates free radicals that are
quenched by GSH, is one of the mechanisms of GSH depletion.13,14, 36, 37,38 Several
studies have shown that PLWH have subnormal plasma levels of GSH39,40,41 and elevated
levels of inflammatory biomarkers including C-reactive protein24, 42 and tumor-necrosis
factor alpha (TNF-!).42
Sekhar et al.33 examined whether inflammation in HIV was linked to GSH
deficiency and tested whether GSH improvement could lower the elevated plasma
concentrations of hsCRP and TNF-α by using nutritional oral supplementation of glycine
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and cysteine.33 In this study, ten HIV-infected men received oral supplementation of
cysteine (0.81 mmol/kg/d) in the form of n-acetyl cysteine (NAC) and glycine
(1.33mmol/kg/d) for 14 days. They measured (1) inflammation biomarkers (hsCRP and
TNF-α), (2) reduced and total GSH, (3) total body fat, (4) insulin sensitivity, (5)
mitochondrial fuel oxidation, and (6) reactive-oxygen species. Key findings of this study
were that oral supplementation with cysteine and glycine increased intracellular GSH
levels by 41%. Simultaneously, there was a 55.4% decrease of plasma levels of hsCRP
and 19.2% for TNF-α. These findings support the possibility of a relationship in rising
concentrations of GSH in patients infected with HIV was linked to a considerable and
rapid decline in the concentrations of hsCRP and TNF-α. The authors’ finding is
significant since its implications are therapeutic and mechanistic, as they suggest that
GSH deficiency can cause inflammatory paths activation in HIV infection. Additionally,
a nutritious routine utilizing n-acetyl cysteine, as a cysteine donor, as well as glycine to
create a rise in concentrations of GSH may decrease inflammation in HIV. Although this
study indicates that a nutritional approach using NAC and glycine may be beneficial
among HIV-infected persons by improving GSH concentration and lowering
inflammation, it had several weaknesses. The research was conducted in a small group of
only male participants, the length of the supplementation was short, and the study lacked
a placebo group.
In another study, Alfonso et al.43 examined whether NAC supplementation had a
potential effect on reducing levels of oxidative stress and inflammation among
participants with a history of asbestos exposure but otherwise healthy. Sixty-six male
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subjects between the age of 40 and 70 years were randomized into either the
supplemented (n=34) or placebo group (n=32). This was a four-month randomized
clinical trial, where the intervention group received 1800 mg/day of NAC and the placebo
group received tablets similar in appearance and taste. They measured total combined
thiols (cysteine, glutathione, cysteinyl, glycine homocysteine), and markers of
inflammation (CRP and TNF-α). The researchers did not find any variations between the
active and placebo group in serum levels of cysteine, cysteinyl, glycine, glutathione and
homocysteine. Additionally, none of the subjects had TNF-α above the limit of detection,
besides, the investigators did not find considerable variations in CRP. The findings of
this study showed that NAC supplementation did not increase antioxidant capacity or
improve inflammation biomarkers. Ultimately, there was no evidence that NAC
replenished combined thiols of healthy subjects who have previously been exposed to
asbestos. However, the investigators believe that these negative findings may have
resulted from low supplementation doses, the clinical conditions to reach physiological
replenishment of thiols are not well established in alveolar lavage compared to plasma,44
and/or biased selection of the subject.43
Borges-Santos et al.,30 on the other hand, were able to show that dietary
supplementation with either N-acetyl cysteine (NAC) or glutamine (Gln) have positive
effects on levels of plasma glutathione, and its three component amino-acids in PLWH.
The study recruited 32 participants in total, 12 PLWH on stable ART, and 20 healthy
participants. The 32 participants were randomized to receive either NAC 1g/d or Gln 20
g/d, in addition to their usual diet for seven days. Participants were followed for another 7
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days without supplementation as a washout period. The levels of glutathione and its three
component amino-acids were significantly lower in the HIV+ group at baseline and under
the reference levels of healthy volunteers after the 7-day supplementation. The authors
found that patients with HIV demonstrated a higher oxidized GSH and decreased
concentration of GSH and other amino acids except for homocysteine. The patients with
HIV responded to the NAC through increasing amounts of amino acids that contain
sulfur and GSH, and balanced levels of GSH and taurine within the control group. The
researchers found that Gln and NAC supplements created a rise in Gln, methionine,
taurine and GSH, and lowered serine in HIV+ patients. Additionally, supplementation of
NAC resulted in considerable rises in homocysteine and cysteine, while supplementation
of Gln created a rise in glutamine concentrations. Gln and NAC supplements were also
found to have similar impacts on levels of plasma in Gln, glutamic acid, taurine and
methionine.
Similar observations were also made by Nguyen et al.32 showing that reduced
levels of cysteine and glycine in serum affect levels of glutathione. This investigation
tested if GSH deficiency can be improved by supplementing with GSH precursors (NAC
and Gln) and aimed at improving GSH level, expecting that there will be improvement in
fed and fasted mitochondrial fuel oxidation. They recruited eight PLWH men 50 years
and older, they are all on stable ART, without AIDS, and free of non-communicable
disease. Subjects received 0.81 mmol/kg/d of NAC and 1.33 mmol/kg/d of Gln for two
weeks, in an open-labeled design. The study measured insulin sensitivity, body
composition, and muscle strength. The investigators used a combination of stable-isotope
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tracers, calorimetry, hyperinsulinemic-euglycemic clamp, and dynamometry to measure
GSH synthesis, fasted and insulin-stimulated (fed) mitochondrial fuel oxidation, insulin
sensitivity, body composition, anthropometry, forearm-muscle strength, and lipid
profiles. From the research, the authors found that reduced synthesis leads to deficiency
of GSH in the patients, which can be restored through supplementation using cysteine
plus glycine. It was also found that GSH enhancement occurred together with significant
improvement in fed and fasted mitochondrial fuel oxidation. As such, benefits including
dyslipidemia, muscle strength, anthropometry, body composition and insulin sensitivity
were observed.
One drawback was that the mean age of the subjects was 56 years and aging is
associated with oxidative stress,45 also it has been seen that supplementation among the
older population restores GSH and decreases oxidation.
In conclusion, most studies in the literature have shown that oral supplementation
of N-acetylcysteine (NAC), glutamine and glycine in PLWH increased plasma levels of
GSH and decreased inflammation. The supplementation period in those who found
beneficial effects were mostly short, no longer than fourteen days, and the studies
included a small number of participants.13,15,16,25,26
In summary, high levels of inflammation in PLWH have been associated with
GSH deficiency,16 and excess mortality.46 Therefore, testing whether supplementing
NAC could increase levels of GSH, and lower the elevated plasma concentrations of CRP
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and TNF-α needs to be further investigated for longer period of time as potential targets
for intervention.
Oxidatively damaged DNA and Antioxidants supplementation
Failure to repair DNA strand breaks is more common in lymphocytes because
they get more rapidly depleted of catalase and/or GSH than other cell types. DNA repair
capacity is related to levels of intracellular antioxidant activity, which is potentially
diminished in PLWH.47 Increased levels of oxidative stress increase oxidative damage to
DNA, which might influence HIV disease progression.48
Nygren et al.49 measured DNA damage in cultured skin fibroblasts from patients
with GSH deficiency. Treatment varied among patients between acidosis, vitamin C
and/or vitamin E. They measured DNA single strand breaks utilizing comet assay. They
expected that GSH deficiency makes cells more prone to oxidative DNA damage leading
to apoptosis and neuronal death; however, that was not observed. Although they establish
that GSH might not completely protect damaged DNA, yet they found that high levels of
oxidative DNA damage are more prone to ionizing radiation. Therefore, the intrinsic cell
protection against oxidative stress is dependent on the background levels of damaged
DNA. This study is of significance because PLWH have lower levels of GSH, which may
contribute to heightened DNA damage, thatsuggests a potential benefit of
supplementation for this population.50
Duthei et al. 51 conducted a double-blinded supplement study, on healthy smokers
and nonsmoker volunteers for 40 weeks. They aimed to measure antioxidant capacity in
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plasma and oxidative DNA damage. Half of each group received either antioxidant
regimen (vitamins C and E, and β-carotene), or placebo. Similar to our study, the comet
assay was used to measure DNA damage and the rate of oxidized DNA pyrimidines was
the specific oxidative damage index. By week 20, a significant decrease among the entire
supplemented population, smokers and nonsmokers, in DNA damage was observed. This
reveals that antioxidant supplementation protects the DNA from endogenously ROS
production. Also, Jaruga et al.2 investigated the effect of antioxidant vitamins on HIV+
patients on the DNA bases and observed that supplementation reduced the levels of DNA
oxidative damage. In this study, ten healthy volunteers (controls) were compared to 30
PLWH drug users and 15 HIV-negative drug users. Only the HIV+ patients were either
supplemented with vitamins A, C and E or placebo. Levels of damaged DNA before and
after supplementation were quantified from isolated chromatin from lymphocytes using
gas chromatography/isotope-dilution mass spectrometry with selected-ion monitoring
(GC/IDMS-SIM) to measure levels of modified DNA bases. They observed considerable
rises in the quantity of the altered DNA bases in patients with HIV relative to the control
cluster. There was a greater concentration of thiobarbituric acid reactive substances
(TBARS), while antioxidant enzymes (superoxide dismutase and catalase) activities
decreased in the cluster of patients infected with HIV compared to the control cluster. It
was also found that supplementation of vitamins led to considerable decline in the
degrees of all altered DNA bases in comparison to subjects who were given the placebo.
The researchers also observed a decrease in TBARS, along with a reestablishment of the
enzymes activity. Antioxidant supplementation resulted in reduction in levels of modified
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DNA compared to patients who received placebo As such, the data suggest that treatment
using antioxidant vitamins can be beneficial to individuals infected with HIV
Hashimoto et al. evaluated GSH influence on DNA damage and changes in blood
chemical parameters among young and aged rats.5 They measured GSH and DNA
damage in the liver and kidneys of rats. GSH was measured using a BIOXYTECH GSH
400, commercial kit, and comet assay for DNA damage. They found that DNA damage
was higher in aged rats’ liver and kidney compared to young rats. However, they found a
negative relationship between GSH and DNA damage, which is conflicting with other
findings in the literature.52
The researchers5 found a negative relationship between DNA damage and GSH
content in the kidney and the liver. L-buthionine (S,R)-sulfoximine (BSO; 0, 5, 20 mM)
that inhibit production of GSH, was given through water, which resulted in considerable
decrease in levels of GSH in the kidney, lung, liver and heart without damaging DNA in
the organs. The results indicated a negative relationship between DNA damage and GSH
during aging; however, GSH depletion because of BSO did not have an impact on DNA
damage or levels of blood chemistry under the conditions of the study.
Echevarria et al.53 investigated the in-vitro effect of ascorbic acid on viral load
reduction and protection against oxidative damage in the DNA of HIV-infected T-cells.
Oxidative DNA damage was measured by the comet assay. The investigators suggest that
exposure to ascorbic acid seems to provide some protection to HIV infected CD4+ Tcells. Researchers found decreased DNA damage in HIV-1 positive T-cells that had been
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exposed to ascorbic acid. When concentrations were increased, DNA damage was
decreased, suggesting that DNA of HIV-1 T-cells was impacted when treated with
ascorbic acid.
It has been documented that chronic HIV infection increases the production of
reactive oxygen species (ROS), which damages DNA progressively.52 The body’s
antioxidant defense system, of which GSH is an important component, protects the DNA
from ROS. 54 Considering the association between GSH depletion and DNA damage, an
antioxidant regimen should be considered in PLWH.
In summary, the evidence points to the relationship between depletion of
GSH and DNA damage, a condition found among PLWH, as well as showing a
relationship of excessive ROS with depletion antioxidant defense system resulting in
DNA damage in the general population. In view of these findings, it is important to
establish the long-term effect of antioxidant supplementation in chronically infected and
treated PLWH to delay co-morbid conditions associated with excessive oxidative stress,
such as liver fibrosis, cardiovascular disease, prediabetes, diabetes, and cancers.
HIV, ART and Inflammation
Antiretroviral therapy (ART) availability extends the life expectancy in HIVinfected persons.55,56,57 However, individuals successfully treated with ART are at higher
risk to develop chronic conditions such as atherosclerosis, either because the PLWH are
aging or because of secondary effects of the disease or its treatment.58 This population
exhibits greater development of some non-AIDS comorbid diseases such as chronic
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kidney disease, liver disease, diabetes mellitus, coronary heart disease and atherosclerosis
which are associated with inflammation.12,59,60,61
HIV infection, both treated and untreated is associated with chronic inflammatory
diseases; thus, biomarkers of inflammation including CRP and TNF- ! are elevated. 62,63
Moreover, these inflammation biomarkers are correlated with mortality among HIVinfected individuals.64 Therefore, it is helpful to examine inflammatory biomarkers to
predict potential clinical outcomes.38,33 Since ART prolongs life expectancy among
PLWH, aging in this population is associated with an increased risk of age-related
morbidities.65 Although chronic HIV infection is associated with specific mechanisms
that may contribute to comorbidities associated with inflammation, such as bacterial
translocation and chronic immune activation, other senescent mechanisms may act in
parallel to aggravate its effects.39 There is a growing evidence indicating the crucial role
of oxidative stress and resulting changes in redox state in numerous diseases including
those associated with chronic inflammation, including cancer, AIDS/HIV, and aging.66
Senescence also contributes to oxidative stress, therefore, novel interventions need to be
implemented to control both oxidative stress and inflammation in PLWH.
SUMMARY
Inadequate levels of plasma GSH in PLWH are associated with
accelerated disease progression, higher susceptibility to co-infection with TB, and
diminished survival.13,14,21 ,67,68,69 Preliminary studies in the literature have suggested that
supplementation with oral cysteine as n-acetyl cysteine (NAC), glycine, and glutamine as
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L-glutamine

(Gln) improves cell and plasma GSH levels.15,16,47 Furthermore, inadequate

GSH concentration is associated with inflammation, oxidative stress, DNA damage, rate
of cellular aging, obesity, and insulin resistance.15,16,70 Most of the supplementation
studies with GSH suggest that achieving adequate levels in plasma or cells decreases
oxidative stress in HIV infection.49,50 ,71,72,73,74,75 Nguyen et al.15 found that HIV infected
individuals older than 50 years had significant GSH deficiency. Oxidative stress can
contribute to chronic inflammation and the development of a variety of pathologies found
in many chronic diseases.76 Furthermore, elevated levels of oxidative stress seem to be
associated with two important cardiovascular risks: metabolic syndrome and
inflammation in PLWH.77
In summary, the studies of supplementation with glutathione and its precursors on
the effect of plasma and cell glutathione and overall oxidative stress and inflammation
are small in sample size and short in duration, and the evidence on PLWH on stable ART
is lacking. Also, there is no previous or existing literature about conducting comet assay
in PLWH to measure the effect of oxidative stress and antioxidant supplementation on
damaged DNA. Therefore, implementing innovative interventions to demonstrate the
safety and efficacy of these antioxidants is significant and warranted.
Oxidatively damaged DNA is a common measure of oxidative stress. Besides,
one of the commonly used methods to measure DNA oxidative damage is the comet
assay.78 GSH plays a major role in scavenging the free radicals that are produced by high
levels of inflammation. Once levels of GSH are depleted, the antioxidant defense system
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is affected. An important approach to prevent damage to DNA through antioxidant
pathways, is that antioxidant supplementation could decrease levels of damage.79
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CHAPTER III: JUSTIFICATION AND METHODOLOGY

Justification for the Characteristics of the Design:
a) Why oxidative stress in PLWH in Miami-Dade County: HIV infection leads
to increased oxidative stress which may in turn lead to faster development of HIV-related
chronic diseases.1,2 Hence, antioxidants might have a significant adjuvant role in the
treatment of HIV/AIDS.1 The MASH cohort is recruiting 1,500 participants, half of
whom are PLWH. Miami-Dade County currently has more than 27,000 PLWH and a
concentrated and growing HIV epidemic, which makes the development of interventions
to improve their quality of life, prevent and treat co-morbidities and delay mortality
meaningful and important research goals.
b) Why supplementation with NAC and glycine: Glutathione deficiency
contributes to oxidative stress, which plays a key role in aging, the pathogenesis of HIV
and cardiovascular disease.3 Only a few studies have supplemented N-acetyl cysteine
(NAC), glutamine and glycine orally in PLWH, but the reports from these trials
suggested beneficial effects on concentration of GSH, which is an important intrinsic
antioxidant in cells and in peripheral blood.4,5,6 Previous supplementation studies,
however, were mostly conducted for a short period of time using a small number of
participants. Therefore, a randomized clinical trial of supplementation with these
antioxidants, for a longer period, with adequate sample size is warranted.
c) Why a randomized controlled trial of supplementation: Randomized
controlled clinical trials of nutritional supplementation are considered to be the most
reliable design to develop evidence-based interventions,7,8, 9 as long as they have
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adequate sample size, internal/external validity and sustained for an adequate time
periods.9
d) Why measures of oxidative stress: (GSH, DNA damage) Most of the
supplementation studies with GSH, and its components, such as N-acetyl cysteine and
glycine,4,5,6 suggest that achieving adequate levels in serum or cells decrease oxidative
stress in HIV infection. 10,11,12,13,14,15,16As a measure of oxidative stress, we selected the
ratio of oxidized glutathione to total glutathione and % DNA tail, which have been
associated with oxidative stress in other HIV studies.17,18,19 DNA damage is a common
measure of oxidative stress.20 Besides, one of the commonly used methods to measure
DNA oxidative damage is the comet assay.21 There are no previous studies that
conducted the comet assay with HIV infected blood. Al-Salmani et al.22 developed an
advanced protocol, where they decreased the size that the comet assay occupies on the
bench.22 Moreover, this novel method was examined once with whole blood.
e) Why measures of inflammation: Elevated levels of oxidative stress seem to
be associated with two important cardiovascular risks, metabolic syndrome and
inflammation in PLWH.23 Two well accepted measures of inflammation that have been
used in other HIV-related studies are proposed for this study: serum hrCRP,24,25,26,27,28
and TNF-α, a pro-inflammatory cytokine.24,25
f) Why the selected inclusion/exclusion criteria: will be selected from the
MASH cohort because this is a well-characterized cohort with a documented history or
medications (types and length of ART), measures of disease progression (HIV viral load
and CD4 cell count), and the participants’ compliance with study visits is known.
Therefore, we can determine during the screening visit their compliance with their
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MASH study visits and their measures of adherence to medication such as viral load ≤
400 copies/mL, and, using this information, exclude those who are non-adherent or noncompliant.
The HIV, HCV and HBV status of MASH participants are also known, as well as
their age and BMI. BMI ≥ 30 kg/m2,29 age ≥ 65 years of age,30,31 and participants with
Hepatitis B or C32,33 will be excluded, in order to control for well-known factors
associated with increased oxidative stress in this population.34 To avoid confounding
effect of other nutritional supplement, we will exclude participants who are on nutritional
supplements. We are also excluding pregnant women who are required to take
supplements during pregnancy.7

Population, Recruitment, Inclusion/Exclusion Criteria
1. Population:
Subjects for this study were recruited from the Miami Adult Studies on HIV
(MASH) cohort at the Florida International University (FIU) Research clinic at the
Borinquen Health Center, Miami-Dade, Florida. The study was reviewed and approved
by the FIU Institutional Review Board.
2. Intervention:
This study was a double-blinded randomized controlled trial (RCT) with a 3month intervention period. Participants were randomized to receive either NAC (100
mg/day) and glycine (100 mg/day) by NOW FOODS or Placebo, which was cellulose by
Medisca. Participants visited the clinic at baseline and once a month for three months. At
baseline and each visit, blood was collected to measure markers of oxidation. Throughout
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the study, participants were asked not to take any other vitamin supplementation.
Monthly phone calls were made and pill count was administered to assess their adherence
to the intervention regimen, and compliance with clinic visits. The study took place
between March 2018 – March 2019.
3. Eligibility and Inclusion/Exclusion Criteria
Inclusion criteria:
1) Age ≤ 65 years old
2) Participating in MASH cohort
3) Able to provide written consent for this study
4) BMI ≤ 30 kg/m2
5) HIV positive by documentation
6) On stable ART for more than 6 months
7) Free of co-morbid diseases (uncontrolled diabetes, symptomatic cardiovascular
disease, free of HCV, HBV as confirmed by test)
8) Undetectable viral load.
9) English speakers only
10) Not on nutritional supplements for the past three months.
Exclusion criteria:
1) Not meeting the inclusion criteria
2) Pregnancy or intention to become pregnant
3) Using nutritional supplements
4) Participating in other blinded clinical trial.
5) Spanish speakers
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6) Not willing to participate
4. Recruitment:
Subjects for this study were screened and recruited from the MASH cohort at FIU
Research clinic in the Borinquen Health Center, Miami-Dade, Florida. This recruitment
strategy has the advantage that the cohort is a well characterized and consists of a large
number of PLWH (more than 800 participants), the participants’ locator information is
available to recruiters for follow-up, and their clinical records are available with the
participant’s permission.
The study statistician provided a list with the participants meeting the inclusion
criteria. For further accuracy the list was assessed extensively for adherence to
medications and Cohort visits, spoken language, supplement intake at each visit, and all
inclusion criteria before contacting the participants. To ensure that the participants are
going to be adherent and compliant with the clinical trial visits and supplements,
adherence to the MASH cohort visits and HIV medications were taken into consideration.
Moreover, each participant was contacted via phone call or contacted when they come for
a Cohort visit, to ensure: they spoke English, they are not on any supplements, and
willing to participate. The study was explained thoroughly, on the phone or in person in
the clinic. After this further assessment, participants were recruited to the study and their
information was sent to the pharmacy to have their pills prepared.
Before contacting the participants and after assessing each participant on the list,
their visit dates were checked to know when they will be attending the closest clinic visit
to the cohort, and within couple of weeks before the visit, the clinic staff was informed
that this participant will be screened after his/her appointment, to allow 10-15 minutes to
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explain this study and obtain consent if subject was eligible and willing to participate. If
the participant’s closest visit was not recent they were contacted via phone for a prescreening and initial recruitment.
Phone call recruitment: As some of the eligible participants have already visited
the clinic for their annual or semiannual visit, they were contacted via phone to confirm
their preferred contact information (phone number), then made sure they are not on any
supplements for the past three months. After asking all the question and checking if
participants met all inclusion criteria, the clinical trial was explained thoroughly and
stopped at each section to make sure if participant has any questions. Before confirming
that participants were eligible, they were asked once again if they understood the study
and if they have any further questions. Finally, an appointment was made for a baseline
visit and pill dispensation. Usually, they were given an appointment a week after the
phone call to allow the pharmacy to randomize participants and prepare the supplement.
The FIU pharmacy was provided with the information needed the same day the phone
call was completed.
Clinic recruitment: while assessing the participants’ eligibility, some had their
cohort visits within the week or in couple of weeks. Hence, they were screened in person
and recruited at the same day they come for a cohort visit. They were told about the
clinical trial after they completed their cohort visit. Once they agreed to participate, they
signed consent document then given an appointment for one week later.
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Intervention/Clinical Trial:
A.

Randomization:

Following the screening eligible subjects were identified; participants were
randomized into either the intervention arm or control/placebo arm. A computer program
to perform stratified randomization with the use of a blocked randomization technique
was used under the supervision of the study statistician.
This study is a double-blinded clinical trial; therefore, the study statistician prerandomized 70 subject to one of two groups (1 or 2). Then the pharmacist at the FIU
pharmacy defined each group and as they were provided with subjects willing to
participate they were placed in the group following a chronological order.
FIU Pharmacy:
The FIU Pharmacy packaged the study pills in a double-blind fashion to reduce
the potential for observer and participant bias, and to implement treatment masking.
Study Setting:
The activities for this study were conducted at the FIU Research clinic in the
Borinquen Health Center, Miami-Dade, Florida, and in the FIU laboratories where most
of the laboratory tests were performed. The FIU Pharmacy randomized and bottled the
supplements. Participants were enrolled in this study for three months, with a monthly
visit. Hence, they visited the clinic for baseline (BL), visit two (on month into the study),
visit three (two months after BL), and visit four (the last visit, three months after the BL)
B.

Consent:

Following the pre-consent, phone consent, those participants signed the consent in
the clinic when they came for this study baseline visit.
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After identifying eligible participants from the list provided, phone calls were
made to recruit participants and a pre-consent was conducted. In the phone consent the
study was explained thoroughly to participants, asking them about their willingness to
participate, if they have any questions, and set an appointment a week from the phone
call. Once the participant came for the initiated study first visit/baseline visit, the study
was explained again before signing the consent. Some eligible participants were
interviewed and consented when they came for a cohort visit and set their appointment
for the clinical trial baseline visit.
C.

Pharmacy:

Only the statistician and the pharmacist had knowledge of the randomization
groups in order to prepare the pills. The pharmacist received the information of each
subject willing to participate after the consent process and had the blinded supplement
ready for pick up to the clinic. For dispensation.
Vials:
The vials were covered to avoid bias. The pharmacy added minimal general
information on the vial. This information was limited, which included: participant clinical
trial ID, cohort ID, and date of birth. The pill bottles were stored in the pharmacy where
all the pill preparation took place until they were delivered to the clinic.
Pills:
Dispensation:
Pills were dispensed at the baseline visit. Each participant received two bottles
with 100 tablets in each. Participants were asked to take one pill from each bottle daily,
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with a total of two pills daily. Bottles were defined as bottle A and B, to help the
participant differentiate between them.
Pill count:
After the baseline visit, the participants brought the bottles for pill count to ensure
compliance. Hence, three pill counts were performed for each participant that completed
the study.
Table 1: Variables collected at each visit and variables obtained from the MASH cohort:
Variable/visit
Glutathione
(Blood)
CRP
DNA damage
(Blood)
BMI
Bioelectrical
impedance
analysis (BIA)
24-h dietary
recall
Pill count

Baseline
X
From MASH cohort
X
From MASH cohort
X
X
From MASH cohort
X
From MASH cohort

Visit 2

Visit 3

Visit 4
(end of study )
X

X

X

X
From MASH cohort
X

X

X

X
X

X
From MASH cohort

X
X

X

X

Variables obtained from the MASH Cohort:
All obtained data from the parent study were obtained from the cohort most recent
visit to the clinical trial.
Demographics, Anthropometric measurements, glutathione, CRP, 24-hour
recall and cocaine use were obtained from the MASH cohort.
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Demographics were available on REDCap and obtained upon the consent of the
participants. Including, gender, age, and ethnicity.
CD4+ and Viral Load were obtained from the medical reports that participants
provide when they came for a cohort visit. As they were assessed to confirm participants
eligibility.
Glutathione and CRP were obtained for the baseline of the clinical trial from the
recent cohort visit.
Anthropometric measurements were obtained from the recent cohort visit,
which was available from REDCap. Height was obtained using a stadiometer and it was
obtained only at the cohort baseline visit. Weight was measured on a scale with light
clothing and was measured at each visit. Body Mass Index was measured in kg/m2.
Bioelectrical impedance analysis (BIA), were measured without shoes and socks.
Electrodes were placed on the participant’s right wrist and hand, and right foot and ankle.
Cocaine use was obtained from the self-reported questionnaire and confirmed by
the urine toxicology test.
24-hour dietary recalls were obtained from a self-report questionnaire at the
recent cohort visit to the clinical trial baseline.
Variables collected during the clinic visit for this clinical trial:
At each visit approximately 1-3 mL of blood was drawn to measure DNA
damage. At the last visit GSH was measured for this study from the blood drawn.
Baseline variables were all available and obtained from the parent study except
for the DNA damage (comet assay) which was analyzed from the blood drawn at the
baseline visit.
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Visit two and visit three: for this study blood was drawn to measure DNA
damage, weight recorded to measure BMI, and pill dispensation and pill counts were
conducted to assess adherence.
Visit four: blood was drawn to measure GSH and DNA damage, bioimpedance
was measured for fat % and BMI, pill count was recorded to assess adherence.
D.

Blood draw (venipuncture):

At each visit, including the baseline, blood was drawn by trained personnel.
The study nurse drew blood for each participant at baseline, visit two, visit three,
and visit four for DNA damage. Blood was also drawn at baseline and visit four to
measure GSH.
E.

Compensation

Each participant was compensated $10 at the end of each visit.
F.

Blood aliquots and transportation:

Labels:
Labels for all specimens obtained during the clinic visits were printed as the
participant arrived to the clinic and included the participant’s clinical ID, amount of
blood, number of tubes and date.
For baseline and visit four we collected two lavender 1 mL tubes for GSH. For all
other visits, we collected eight aliquoted tubes of blood for DNA (comet assay) with 25
µL and two tubes of 50 µL. After aliquoting, the tubes were stored at -20 C for a
minimum of 20 minutes then transported on dry ice to transport to the FIU oxidative
stress group (OSG) freezer and stored at -80 C until analysis.
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G.
I.

Laboratory analysis conducted for this study:
DNA damage: Comet assay

Material:
Ø

COMPAC-50 High Throughput Comet Electrophoresis System, was

purchased from Cleaver scientific LTD.
Ø

Human 8-oxoGuanine DNA Glycosylase (hoGG1), was purchased from

Fisher Scientific
The comet assay assays were conducted from February 2019 to May 2019. Prior
to conducting the comet assay experiments with the HIV blood samples collected during
the clinical trial, the protocol was tested with rabbit blood to ensure that the enzyme
modified and alkaline comet assay protocol for whole blood was ready to be
implemented in two different laboratories. Each experiment took two consecutive days
aside from scoring the slides. All reagents and necessary materials were prepared ahead
of time for each experiment. At each experiment not only HIV blood sample were
analyzed, but also positive control slides, which were Hacat cells were also analyzed in
the experiment. The HaCat cells were prepared by Abdulahdi, member of the OSG. We
included four types of Hacat cells: 1) HaCat without treatment or UVB exposure
(control), 2) HaCat +hoGG1, 3) HaCat exposed to UVB (0.5 J/cm2), 4) Hacat exposed to
UVB (0.5 J/cm2)+ hoGG1.
II.

Glutathione
Material:
Ø

Arbor Assay Glutathione Colorimetric Kit, was purchased from Fisher

Scientific
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The baseline results were opt from the closest cohort visit. Besides, the blood
drawn at the end of the study was analyzed to analyze glutathione after the completion of
the supplementation.

References:
1

Singh G, Pai RS. Dawn of antioxidants and immune modulators to stop HIVprogression and boost the immune system in HIV/AIDS patients: An updated
comprehensive and critical review. Pharmacol Rep. 2015;67(3):600-605. doi:
10.1016/j.pharep.2014.12.007.
2

Suttajit M. Advances in nutrition support for quality of life in HIV+/AIDS. Asia Pac J
Clin Nutr. 2007;16 Suppl 1:318-322.
3

Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its
implications for health. J Nutr. 2004;134(3):489-492.
4

Nguyen D, Hsu JW, Jahoor F et al. Effect of increasing glutathione with cysteine and
glycine supplementation on mitochondrial fuel oxidation, insulin sensitivity, and body
composition in older HIV-infected patients. J Clin Endocrinol Metab. 2014
Jan;99(1):169-177. doi: 10.1210/jc.2013-2376.
5

Sekhar RV, Liu CW, Rice S. Increasing glutathione concentrations with cysteine and
glycine supplementation lowers inflammation in HIV patients. AIDS. 2015;29(14):1899.

6

Herzenberg LA, De Rosa SC, Dubs JG et al. Glutathione deficiency is associated with
impaired survival in HIV disease. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1967-72.

7

Siegfried N, Irlam JH, Visser ME, et al. Micronutrient supplementation in pregnant
women with HIV infection. Cochrane Database Syst Rev. 201;14;3:CD009755. doi:
10.1002/14651858.CD009755.
8

Irlam JH, Siegfried N, Visser ME, Rollins NC. Micronutrient supplementation for
children with HIV infection. Cochrane Database Syst Rev. 2013; doi:
10.1002/14651858.CD010666.

46

9

Academy of Nutrition and Dietetics. Evidence-based manual for systematical review of
the literature. 2012. www.eatright.org.
10

James JS. Stanford NAC study: glutathione level predicts survival. AIDS Treat News.
1997;(No 266):1-5.
11

Chakravarti B, Chakravarti DN. Oxidative modification of proteins: age-related
changes. Gerontology. 2007;53(3):128–139.
12

Sekhar RV, Patel SG, Guthikonda AP, et al. Deficient synthesis of glutathione
underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine
supplementation. Am J Clin Nutr. 2011;94(3):847–853.
13

De Rosa SC, Zaretsky MD, Dubs JG et al. N-acetylcysteine replenishes glutathione in
HIV infection. Eur J Clin Invest. 2000;30(10):915-29.
14

Breitkreutz R, Pittack N, Nebe CT et al. Improvement of immune functions in HIV
infection by sulfur supplementation: two randomized trials. J Mol Med. 2000; 78:55–62.

15

Spada C, Treitinger A, Reis M et al. The effect of N-acetylcysteine supplementation
upon viral load, CD4, CD8, total lymphocyte count and hematocrit in individuals
undergoing antiretroviral treatment. Clin Chem Lab Med. 2002; 40:452–455.
16

Akerlund B, Jarstrand C, Lindeke B, et al. Effect of N-acetylcysteine (NAC) treatment
on HIV-1 infection: a double-blind placebo-controlled trial. Eur J Clin Pharmacol. 1996;
50:457–461.
17

Shin DH, Martinez SS, Parsons M, et al. Relationship of Oxidative Stress with HIV
Disease Progression in HIV/HCV Co-infected and HIV Mono-infected Adults in Miami.
Int J Biosci Biochem Bioinforma. 2012;2(3):217-223.
18

Aukrust P, Svardal AM, Müller F, et al. Markedly disturbed glutathione redox status in
CD45RA+CD4+ lymphocytes in human immunodeficiency virus type 1 infection is
associated with selective depletion of this lymphocyte subset. Blood.1996;1;88(7):262633.
19

Parsons M, Campa A, Lai S et al. Effect of GSTM1-Polymorphism on Disease
Progression and Oxidative Stress in HIV Infection: Modulation by HIV/HCV
Co- Infection and Alcohol Consumption. J AIDS Clin Res. 2013;4(9):10002337.
doi:10.4172/2155-6113.1000237

47

20

Collins, Andrew R. Investigating oxidative DNA damage and its repair using the comet
assay. Mutation Research/Reviews in Mutation Research. 2009; 24-32.
21

Cadet J, Douki T, Ravanat J. Oxidatively generated base damage to cellular DNA. Free
Radic Biol Med. 2010: 9-21.
22

Al-Salmani K1, Abbas HH, Schulpen S, et al. Simplified method for the collection,
storage, and comet assay analysis of DNA damage in whole blood. Free Radic Biol Med.
2011 Aug 1;51(3):719-25.
23

Morimoto HK, Simão AN, de Almeida ER, et al. Role of metabolic syndrome and
antiretroviral therapy in adiponectin levels and oxidative stress in HIV-1 infected
patients. Nutrition 2014; 30 (11–12):1324– 1330.
24

Ghislain M, Bastard JP, Meyer L, et al. Late Antiretroviral Therapy (ART) Initiation Is
Associated with Long-Term Persistence of Systemic Inflammation and Metabolic
Abnormalities. PLoS One. 2015;10(12):e0144317. doi:10.1371/journal.pone.0144317
25

Calza L, Magistrelli E, Danese I, et al. Changes in Serum Markers of Inflammation and
Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment
with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz. Curr HIV Res.
2016;14(1):61-70.
26

Saeedi R, Johns K, Frohlich J et al. Lipid lowering efficacy and safety of Ezetimibe
combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIVpositive patients. Lipids Health Dis. 2015; 19;14:57. doi: 10.1186/s12944-015-0054-x.
27

Missailidis C, Höijer J, Johansson M, et al. Vitamin D status in Well-Controlled
Caucasian HIV Patients in Relation to Inflammatory and Metabolic Markers--A CrossSectional Cohort Study in Sweden. Scand J Immunol. 2015;82(1):55-62. doi:
10.1111/sji.12299.
28

Young LC, Roediger MP, Grandits G et al. Relationship between inflammatory and
coagulation biomarkers and cardiac autonomic function in HIV-infected individuals.
Biomark Med. 2014;8(9):1073-83. doi: 10.2217/bmm.14.27.
29

Redhage LA, Shintani A, Haas DW et al. Clinical factors associated with plasma F2isoprostane levels in HIV-infected adults. HIV Clin Trials. 2009;10(3):181-92. doi:
10.1310/hct1003-181.
30

Smith RL, de Boer R, Brul S et al. Premature and accelerated aging: HIV or HAART?
Front Genet. 2013; 28;3:328. doi: 10.3389/fgene.2012.00328.

48

31

Effros RB. Telomere/telomerase dynamics within the human immune system: effect of
chronic infection and stress. Exp Gerontol. 2011;46(2-3):135-140. doi:
10.1016/j.exger.2010.08.027.

32

Douglas DN, Pu CH, Lewis JT et al. Oxidative stress attenuates lipid synthesis and
increases mitochondrial fatty acid oxidation in hepatoma cells infected with hepatitis C
virus. J Biol Chem. 2015

33

Piciocchi M, Cardin R, Cillo U, et al. Differential timing of oxidative DNA damage
and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. Transl
Res. 2015; (15)00298-4. doi: 10.1016/j.trsl.2015.08.012.
34

Baum MK, Sales S, Jayaweera DT et al. Coinfection with hepatitis C virus, oxidative
stress and antioxidant status in HIV-positive drug users in Miami. HIV Med.
2011;12(2):78-86. doi: 10.1111/j.1468-1293.2010.00849.x.

49

CHAPTER IV: The Effect of Three-Month Supplementation on Oxidatively
Damaged DNA in PLWH from the MASH cohort
Introduction
The antioxidant defense system is altered in people living with HIV (PLWH),
causing excessive production of reactive oxygen species (ROS).1 During the progression
of the human immunodeficiency virus (HIV) to its more advanced terminal form the
acquired immunodeficiency disease syndrome (AIDS), the antioxidant defense system is
altered, and the production of reactive oxygen species (ROS) is increased.1 The
production of excessive ROS leads to DNA damage.2 It has been observed that PLWH
present damaged DNA bases compared with HIV-seronegative, which may be a
contributor to the progression of the infection to acquired immune deficiency syndrome
(AIDS).3 Some of the antioxidant defense system functions is to protect the DNA from
being oxidatively damaged by ROS.4 Glutathione (GSH), an important tripeptide that
contributes to the antioxidant system, is abundantly available and is considered to have an
essential antioxidant role. GSH is synthesized from three amino acid precursors, glycine
(Gly), cysteine (Cys), and glutamate (Glu),5 in some cases, such as acute and chronic
infections, these precursors become conditionally essential.6,7 Supplementation with
antioxidant vitamins have been shown to decrease levels of oxidatively damaged DNA
among PLWH.2
Another antioxidant, N-acetylcysteine (NAC) has several important roles,
including energy metabolism, antioxidant, promotes detoxifications, and is used for
treating some diseases.8 NAC has an important role in decreasing toxic states by its
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capacity to prevent excessive ROS production.. 1-4,9,10,11 Ex-vivo NAC supplementation
reduces levels of ROS and protects against the formation of oxidatively damaged DNA.
Lack of glycine (Gly) availability may result in abnormal metabolism of some
nutrients, failure of the immune response, and other undesirable consequences on
health.12 Thus, Gly is considered to be a conditionally essential amino acid to support
growth.13 Gly is a precursor for glutathione, and supplementation has been observed to be
effective in individuals with diabetes, cardiovascular and inflammatory diseases, obesity,
cancer, and metabolic disorders.14 This amino acid also regulates the immune function
and is utilized in several pathways that generate DNA.13 The aim of this study was to
assess the effectiveness of a three-month nutritional supplementation with NAC and Gly
on levels of oxidative stress measured by the levels of oxidatively damaged DNA among
people living with HIV (PLWH).
Methods
Study Design
This was a three-month double-blinded randomized clinical trial conducted from
March 2018 to April 2019. Participants were randomly assigned to receive either NAC
(100 mg/day) and glycine (100 mg/day) or placebo. The participants were recruited from
the Miami Adult Studies on HIV (MASH) cohort at Florida International University
(FIU) Research clinic at Borinquen Health Center, Miami, Florida.
In order for participants to be eligible they had to be HIV-positive, free of comorbid diseases, younger than 65 years old, BMI ≤ 30 kg/m2, and not supplemented with
nutrients for the past three months. The study was approved by the Florida International
University Intuitional Review Board.
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The clinical trial took place in the MASH cohort FIU Borinquen research
clinic,where the clinical and laboratory data were collected. Participants visited the clinic
once a month, for a total of four visits. At each visit, blood was collected by peripheral
venipuncture for the Comet assay, and a pill count and adherence questionnaire were
administered to assess adherence to the study supplement. Several variables were
obtained from the MASH cohort, which included: height, demographics (ethnicity, age,
and gender), viral load, CD4+ cell count, bioimpedance markers (% fat) and
inflammation biomarkers. Baseline glutathione (GSH), which included total glutathione
and oxidized glutathione (GSSG) in whole blood were obtained from the MASH cohort,
however, blood for this study was specifically collected to assess levels of GSH at the
end of the study, which will be discussed further in the next chapter.
Blood collection and storage
In the clinic, the blood samples were collected by peripheral venipuncture at each visit (2
mL ) in EDTA tubes from 30 subjects. This was then aliquoted in eight 20 µL EDTA
tubes, and the aliquots frozen at – 20 °C for approximately 20 minutes. Then the samples
were transported to the Oxidative Stress Group laboratory in FIU on dry ice and stored at
– 80 °C, until analysis
hOGG1-modified comet assay for whole blood
The alkaline and enzyme modified comet assay was adapted from a recently
described reports.15,16,17,18 We analyzed 5 µL of blood that were suspended in 200 µL of a
pre-warmed low melting point (LMP) agarose. Then 80 µL was dispended to each half of
the pre-chilled (pre-coated with 1% normal melting point (NMP) agarose) microscope
slides on a chilling plate (Figure 1), (Cleaver Scientific, Rugby, UK). After removing the
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coverslips, the slides were incubated overnight at 4 °C in the lysis buffer (100 mM
Na2EDTA, 2.5 M NaCl, 10 mM Tris−HCl, pH 10) containing 1% triton X. The next day
slides were washed once with cold double-distilled water for 10 minutes. Followed by the
enzyme reaction buffer (ERB: 40 mM Hepes, 0.1 KCL, 0.5 mM Na2EDTA + 0.2 mg/ml
BSA, pH 8.00 adjusted with KOH) for 20 minutes. The ERB was prepared as a 10X
stock and frozen at -20 °C in aliquots. Then half of the slides were treated with Human 8oxoguanine DNA glycosylase-1 (hOGG1; New England biolabs, USA); 60 µL of hOGG1
in ERB to a finalconcentration of 3.2 U/mL hOGG1.17 The other half was kept in doubledistilled water for 10 minutes. Following 45 min incubation, the coverslips were removed
and all slides were placed in the slide rack then incubated in the electrophoresis tank
(Cleaver Scientific, Rugby UK) filled with electrophoresis buffer (300 mM NaOH, 1 mM
Na2EDTA, pH≥13) for 20 min. Then the electrophoresis was performed at (300V,
700mA, 150W) for 20 minutes. Then slide-racks were removed from the electrophoresis
tank and placed in the neutralization buffer for 20 minutes (0.4 M Tris-base, at pH 7.5).
This was followed by washing in cold double-distilled water (20 minutes), staining in the
dark with the tank lid closed with propidium iodide (2.5 µg/mL, for 20 min), and lastly
washed the slides in cold double-distilled water (20 min). Slides were left to dry before
analyzing the comets, DNA damage as percentage tail DNA, using Comet IV software,
version 4.2 (Perceptive, UK).
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Fig. 1: Pre-coated microscope slides with 1% normal melting point
(NMP)agarose) on a chilling plate

Statistical Analysis
Statistical analysis were performed using Prism Version 5 software (GraphPad
software) and SPSS 20. The effects of the study supplements were compared using an
intent-to-treat analysis initially, and then modified by adherence to the supplements.
Descriptive statistics were used to characterize the study population at baseline, and to
compare the two study groups. Student’s t-tests were used to assess mean differences in
changes of oxidatively damaged DNA among intervention and supplementation group.
Linear regression models were used to determine the relationship between DNA damage
and pill adherence, and to assess the effect of supplementation on changes in oxidative
stress from baseline to the end of the study. In GraphPad Prism the data were evaluated
using paired analysis to compare groups and time points. The level of significance was
set at p<0.05. Spearman rho and Pearson correlations were used to determine the nonparametric and parametric correlations
Results
A total of 30 participants were enrolled in the clinical trial, with 15 participants in
each group. The dropout rate for the three months-study was 37%; 47% (n=7) dropped
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out from the intervention group, and 27% (n=4) dropped out from the control/placebo
group.
The randomization achieved similar demographic and biological characteristics in
both groups at baseline (Table 1). A total number of 30 PLWH were enrolled in this
clinical trial, with a mean age of 54.63±6.3 years old, 73.3% (n=22) were Black African
Americans. Hispanic and White both represented 13.3% of the population (n=4 each).
The population consisted of 66.7% males and 33.3% females. The majority of the
population were overweight 70% (n=21). The participants showed 68.4% adherence to
the supplement regimen, where intervention group was 75% adherent while the placebo
group was 63% adherent to the pills (Table 2).
Supplementation significantly decreased levels of DNA damage (SB/ALS +
oxidized purines) in the intervention group p=0.0052 (Fig. 1 C), even levels of SB/ALS
p=0.0305 (Fig. 1D). At the end of the study, week 12, oxidized purines only was not
significantly different in intervention compared to placebo p=0.1142 (Fig. 1D). We
observed similar levels of DNA damage at baseline, as there were no significant
differences between intervention and placebo in SB/ALS (p=0.1175, Fig.1 A and B),
SB/ALS + oxidized purines (p=0.407, Fig. 1A), and oxidized purines only (p=0.1142,
Fig. 1B).
When looking at change in each group from baseline to end of the study we found
that supplementation decreased levels of oxidized purines significantly in the intervention
group p=0.0055 (Fig. 2 C), and change in SB/ALS was not significant, but approaching
significance p=0.0623 (Fig. 2 C and D). There were no significant differences in the
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placebo group in SB/ALS + oxidized purines (p=0.9846, Fig. 2 A), SB/ALS (p=0.7535,
Fig.1 A and B), and oxidized purines (p=0.7697, Fig. 2 B).
Significant differences in change were observed between intervention and control
groups (-4.06±2.8 vs 0.124±3.7, p=0.016). The intervention group showed a significant
decrease in SB/ALS + oxidized purines from baseline to the end of trial with a pvalue<0.05. (Table 3)
A linear regression analysis showed significant association between pill
adherence and decreased levels of SB/ALS + oxidized purines p= 0.015 (Table 4). Mean
levels of SB/ALS + oxidized purines at each one-monthly visit gradually decreased in the
intervention group. However, in the control group, we did not observe a considerable
change. (Table 5, Fig 3 and 4)
Pearson correlation in the change of measures of markers of oxidative stress
and Inflammation
In Table 6, a Pearson correlation was conducted to identify correlations between
the changes in oxidative stress and DNA damage, BMI, and % fat, and inflammation.
BMI was significantly correlated with SB/ALS (r= 0.585, p=0.009).
Discussion:
In our clinical trial, after three-month supplementation reduced levels of oxidative
DNA damage were observed, specifically in SB/ALS and oxidized purines, and in
SB/ALS only. We also found that there participants adherent with their supplementation
reduced levels of oxidatively damaged DNA, SB/ALS and oxidized purines.
Excessive production of ROS may cause imbalance in the antioxidant capacity of
the body antioxidant systems, where DNA and proteins will be exposed to ROS harmful
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effects, leading to DNA damage accumulation and amino-acid oxidation.19,20 Literature
shows that HIV infection causes overproduction of ROS and chronic oxidative stress.2 It
has been observed that PLWH suffer from antioxidant deficiency and decreased
concentration of antioxidant enzymes, which increases the oxidative stress resulting in
oxidative DNA damage. Therefore, supplementing with antioxidants may alleviate the
antioxidant depletion.20
Our findings indicate that NAC and glycine oral supplementation decreased
oxidatively damaged DNA. Our study was similar to that of Jaruga et al,2 who conducted
a clinical trial with supplementing vitamin C, E, and A for the intervention group
compared with a placebo group, and fining that antioxidant supplementation decreased
levels of oxidatively DNA bases among PLWH. In a study conducted among smokers, 21
it was found that antioxidant supplementation was significant in reducing levels of
oxidative DNA damage. Although the population was different, yet, it shows that
antioxidant supplementation of vitamin C, E and β-carotene is able to reduce levels of
oxidative stress when measured at the DNA level.
Supplementation with NAC was significant in decreasing levels of oxidative
DNA damage in human fibroblasts (p<0.001) 22, β-thalassemia (p=0.001)20, and mice
bone marrow (p <0.05).19 Therefore, interventions in the literature support our findings
with the effectiveness of NAC supplementation on oxidatively DNA damage using the
comet assay. This supports our findings, therefore, we supplemented with NAC and Gly
to assess the effectives of both on levels of DNA damage.
Antiretroviral therapy (ART) prolongs life expectancy among PLWH; however,
as they are aging this population is at higher risk for the development of chronic

57

conditions such as atherosclerosis23 and other age-related comorbidities.24 Both human
and animal literature shows increased oxidative DNA damage. Older rats have increased
oxidative DNA damage in their livers and kidneys when compared with younger rats.4 In
agreement with the literature, the average age of our subjects was 54 years, and we found
that oral supplementation of NAC and glycine were significant in reducing oxidatively
DNA damage in this aging population. Because PLWH on ART are living nearly normal
life spans, the risk of developing chronic diseases similar to those of the general
population and rises with aging. Our study shows that a simple and affordable antioxidant
regimen may be beneficial in protecting against accelerated antioxidant damage.
We assessed adherence in this study with pill-counts and an adherence
questionnaire. Adherence was higher in our intervention group, but the drop-out rate was
also higher in this group. Our results in this small sample size, shows that the effect of
supplementation was strong over time, and stronger in those who complied with the
intervention compared with the placebo group.
Literature regarding glycine as an antioxidant is very scarce. Garcia et al. found
that glycine had some effect in preventing DNA damage in a neurodegenerative
disorder.25 While glycine is not considered an effective antioxidant, this study shows it is
a powerful free radical scavenger, and its supplementation may strengthen the enzymatic
antioxidant system through it role in the formation of glutathione. While NAC is known
as an effective antioxidant, it is not possible to determine from this study whether the
antioxidant action took place through the actions of glycine or NAC or both compounds
as they were supplemented together. However, glycine has been shown to have the ability
to protect from oxidative stress by linking protein molecules and form helices. 26
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Strengths and Limitations
The limitations of our study include sample size, large droupout rate, also one of
our limitations is that we did not consider assessing glycine and NAC separately, to
assess potential synergisms when compared with their combined effect. Strengths of our
study, that this may be the first clinical trial to assess the effect of NAC and glycine on
oxidative DNA damage in PLWH using the alkaline enzyme modified comet assay.
Conclusion:
Findings of our study show that supplementation with NAC and glycine is
beneficial among the HIV population in reducing oxidative stress measured by changes in
oxidative DNA damage level over a period of 12 weeks. However, further research is
with larger population conducted over longer period of time with a four-arm factorial
design (NAC, Glycine, NAC and Glycine, Placebo) to identify the specific effect and
assess the magnitude of synergism of the combined group.
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Table 1: Baseline characteristics of study participants by groups
Variable

Placebo
N=15
55.8±5.9

p-value

Age ( years)

Intervention
N=15
53.4±6.9

Gender (M) (%, n)

84 (12)

53 (8)

0.13

BMI ( kg/m2)

26.92±2.3

25.35±3.7

0.173

African Americans
Hispanic
White

66.7 (10)
13.3 (2)
20 (3)

80 (12)
13.3 (2)
6.7 (1)

0.322

CD4+

546±298

577±230

0.759

Viral Load

0.15±0.55

0.066±0.25

0.590

Fat percentage

25.91±5.8

30.12±7.7

0.104

CRP

8.15±16.2

6.02±7.197

0.648

DNA damage (SB/ALS)

4.6375 ±1.95

6.06±2.8

0.118

DNA damage (SB/ALS +
oxidized purines)

16.8±2.9

17.89 ±4

0.407

Total Glutathione (GSH)

962.6±361

902.98±237

0.597

66.8995±38.09

0.999

0.29

Ethnicity( %, n)

Oxidized Glutathione
66.9±37.36
(GSSG)
Data are means ± SD unless otherwise indicated
*Statistically significant, p < 0.05
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Table 2: Percentage of pill adherence according to the pill count and adherence
questionnaire in both groups
Adherence

Non-adherence

N= 13 (68.4%)

N=6 (31.6%)

Control

63.6%
N=7

36.3%
N=4

Intervention

75%
N=6

25%
N=2
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Table 3: Differences in SB/ALS and oxidized purines combined between groups from
baseline to the 12-week visit.
Intervention

Placebo

N= 8

N= 11

4.0612 ± 2.8

0.124 ± 3.7

Data are means ± SD. P is considered significant at < 0.05
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p

0.016

Table 4: Linear Regression Model on the effect of supplementation, age, inflammation
and adherence on changes in oxidative stress damage of (SB/ALS and oxidized purines
combined) from baseline to the 12-week visit.
Variable

B

95% CI

β

t

p-value

Intervention

-3.533

[-6.21, -0.85]

-.457

-2.824

0.014*

Age

-0.041

[ -0.27,0.186]

-0.066

-0.351

0.685

CRP

-0.841

[ -0.13, 0.048]

-0.109

-0.590

0.333

Pill adherence

-4.370

[-7.669, -1.769]

-0.532

-2.769

0.004*

Dependent Variable: SB/ALS+ oxidized purines
*Statistically significant

63

Table 5: Effect of the Intervention and pill Adherence on changes in oxidative DNA
damage (SB/ALS and oxidized purines combined) from baseline to 12-week visit.

Variable

B

95% CI

β

t

p-value

Intervention

-3.652

[-6.131, -1.172]

-.472

-3.122

0.007*

Pill adherence

-4.860

[-7.494, -2.226]

-0.591

-3.912

0.001*

Dependent Variable: Difference SB/ALS + oxidized purines from baseline to Visit 4
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Table 6: Levels of SB/ALS and oxidized purines combined at each visit by groups
Control
17.89 ± 4

Intervention
16.8 ±2.9

P-value
0.407

Week 4
(visit 2)

18 ± 4.2

15.54 ±2.98

0.130

Week 8
(Visit 3)

17.85 ± 3.03

15.69 ± 2.6

0.151

Week 0
Baseline (Visit 1)

Week 12
17.86 ±3.6
13.2 ±2
0.005
(end of trial/visit 4)
Reported as Means ±SD, p-value < 0.05
This table shows levels of DNA damage in SB/ALS and oxidized purines combined, in the
intervention and placebo group at all study visits.

65

Table7: Pearson correlations between study variables

BMI

SB/ALS

oxidized
purines

SB/ALS
+oxidized
purines

Variables

Fat %

Fat%

1

BMI

0.036

1

SB/ALS

-0.141

.585**

1

Oxidized purines only

0.053

-0.015

0.480*

1

SB/ALS +oxidized
purines

-0.332

0.449

0.765**

0.780**

1

CRP

-0.331

-0.175

0.209

0.280

0.173

*significant at a level of <0.05
*significant at a level of <0.001
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CRP

1

Placebo/time 0

A

B

Intervention/time 0

Oxidized Purines Only
30

DNA damage (% tail DNA)

DNA damage (% tail DNA)

30

20

10

SSB+ALS

20

10

0
SB/ALS

Placebo/time 0

Placebo/ week 12
Intervention/week 12
30

20

D
*p=0.0052

* p=0.0304

10

0

Intervention/time 0

Oxidized Purines Only
30

DNA damage (% tail DNA)

C

DNA damage (% tail DNA)

0
SB/ALS
+ Oxidized Purines

SSB+ALS
ns
p=0.1142

20

10

* p=0.0304

0
SB/ALS

Placebo/week 12

SB/ALS
+ Oxidized purines

Intervention/week 12

Fig. 1. Effect of supplementation on DNA damage between groups. hOGG1 modified blood comet
assay was performed to study blood from HIV-infected individuals pre and post nutritional
supplementation. (A) box and whiskers illustrates comet % tail damage with and without hOGG1 at
baseline.. (B) means of levels of SB/ALS and oxidized purine at baseline. (C) box and whiskers illustrates comet %
tail damage with and without hOGG1 at week 12. (B) means of levels of SB/ ALS and oxidized purine at week 12. .
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Placebo week 12
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SB/ALS
+ Oxidized Puries
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D

Intervention week 0
Intervention week 12

SSB+ALS
30
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p=0.1680

DNA damage (% tail DNA)

* P=0.0055
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* P=0.0623
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p=0.0623
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Placebo/time 0 Placebo/week 12
SB/ALS

20

20

0

0

C

SSB+ALS

30
DNA damage (% tail DNA)

DNA damage (% tail DNA)

30

Fig. 2. Effect of supplementation on DNA damage within groups. hOGG1 modified blood comet assay was
performed to study blood from HIV-infected individuals and post nutritional supplementation. (A) box and
whiskers illustrates comet % tail damage among the placebo group with and without hOGG1 at baseline and
end of clinical trial. (B) means of placebo group at baseline and end week 12 levels of SB/ALS and oxidized
purine. (C) box and whiskers illustrates comet % tail damage among the intervention group with and without
hOGG1 at baseline and end of clinical trial. (B) means of intervention group at baseline and end week 12 levels
of SB/ALS and oxidized purine.
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week 0
week 4

* p=0.0036

week 8

ns p=0.38

week 12

DNA Damage (% DNA tail)

25

ns p= 0.72

* p=0.0042

20
15
10
5
0

Intervention

Placebo

Fig. 3.Total DNA damage between placebo and intervention group at week 0, 4, 8 and 12

*p=0.005

*p=0.005

DNA Damage (% DNA tail)

30

20

10

0
Intervention

Placebo

Fig. 3.Total DNA damage, SB/ALs and Oxidized Purines between placebo and intervention group at week
0, 4, 8 and 12
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Supplementary Data:
This alkaline comet assay was not tested previously using whole blood from HIV
infected individuals. Therefore, to ensure that the comet assay was following the
expected conditions we added HaCat cells as positive control to the experiments.
In all the experiments conducted HIV blood samples and HaCat cells were included. We
included four types of Hacat cells, which were: 1) HaCat without treatment or UVB
exposure (control), 2) HaCat +hoGG1, 3) HaCat exposed to UVB (0.5 J/cm2), 4) Hacat
exposed to UVB (0.5 J/cm2)+ hoGG1. Our findings showed that the experiments
conducted met the expected conditions from techniques, pH levels, and scoring. The
figures bellow illustrates bar charts of the % DNA tail for the HaCat cells in four
different experiments.
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hoGG1: human 8-oxoguanine DNA N-glycosylase 1
GSH: Glutathione
GSSG: Oxidized Glutathione
PLWH: People Living With HIV
SB/ALS: Strand Breaks/Alkali-labile Sites
BMI: Body Mass Index
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Chapter V: The effect of NAC and Gly Supplementation on GSH/GSSG in
PLWH from the MASH cohort
Introduction
Oxidative stress occurs when there is an imbalance between reactive oxygen
free radicals and the antioxidant production. Free radicals contain an uneven number
of electrons, which enables them to react freely with other atoms or molecules. These
reactions cause damage to the cells and tissues.1 Antioxidants can donate electrons to
free radicals without becoming unstable themselves. This helps in stabilizing the free
radicals and making them less reactive.2 Oxidative stress occurs when the antioxidants
are not able to stabilize free radicals.3 This happens under certain oxidative and
inflammatory conditions, such as in people living with HIV(PLWH).
HIV is associated with increased inflammation, which leads to the generation
of free radicals. Glutathione (GSH), a tripeptide, is primarily responsible for
providing intracellular antioxidant protection against free radicals. 4,5 It is also
required for optimal functioning of immune system lymphocytes. GSH exists in two
forms; reduced or free GSH performs the antioxidant functions, and GSSG, which is
the oxidized form of GSH after combining with free radicals. 6 In PLWH, glutathione
levels are lowered, thus leading to oxidative stress. This is because HIV supresses
glutathione synthesis by decreasing the availability of its precursor amino acids,
namely cysteine and glycine.7
Administration of GSH precursor amino acids cysteine and glycine may be a
potential solution to address oxidative stress in PLWH as shown previously.8,9,10 A
reduction in inflammatory biomarkers due to increased GSH may bring other health
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benefits, since these biomarkers are linked to an increased risk of non-infectious
comorbidities such as cardiovascular disease in PLWH.
Sekhar et al11 found that increasing GSH concentrations in PLWH resulted in
a significant decrease in inflammation within a short time. To increase GSH
concentrations, nutritional supplements of N-acetyl cysteine and glycine were
administered, and the patients tested for levels of inflammation. A reduction of
inflammation was indicated by reduced plasma concentration of two inflammation
biomarkers: C-reactive protein (CRP) and tissue necrosis factor (TNF-alpha).
According to Gould and Pazdro,12 oral supplements of GSH are not very
effective due to degradation of the tripeptide in the small intestines. However,
administration of GSH precursors glutamate, cysteine, and glycine enhances tissue
GSH synthesis leading to increased levels for antioxidant protection. Addition of
other antioxidant supplements, such as Vitamin C and E, together with GSH
precursors further lowers oxidative stress and rate of tissue damage. The other
supplements are reported to influence the redox performance of GSH and other
antioxidants.13,14
Gupta et al.15 investigated the effects of N-acetyl cysteine on oxidative stress
in PLWH receiving antiretroviral therapy (ART). This was a pilot trial to evaluate the
potential efficacy and safety of a commercially available supplement using a
randomized, double-blind methodology involving PLWH aged 50 years and above. In
this population, the oxidative stress caused by HIV is exacerbated by aging. Oxidative
stress markers were measured after 8 weeks of administration of the treatment. There
was significant increase in levels of reduced GSH and reduction in plasma levels of
GSSG. NAC administration also improved endothelial function and was generally
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well-tolerated by the patients. Therefore, the aim of this study was to assess the effect
of a three-month double blinded nutritional supplementation clinical trial of NAC and
glycine or placebo on GSH levels in PLWH from the Miami Adult Studies on HIV
(MASH) cohort.
Methods:
The design of this study was a double-blinded randomized placebo-controlled
clinical trial (RCT) with a three-month intervention period. Thirty PLWH were
recruited from the MASH cohort from March 2018 –March 2019. Recruitment from
the MASH cohort has the advantage that the cohort is well-characterized and ongoing study and consists of a large number of PLWH (more than 1,100 participants).
The aim of this research was to assess the effect of NAC and glycine supplementation
compared with placebo in PLWH from the MASH cohort. To be eligible, participants
had to be participating in the MASH cohort, HIV status confirmed by documentation
in medical chart, on stable ART for more than six-months, have undetectable HIV
viral load (VL), CD4 cell count 500 or more, BMI ≤ 30 kg/m2, age ≤ 65 years old,
free of co-morbid diseases, English speaker, and not using nutritional supplements for
the past three months. Florida International University institutional review board
approved the study.
Randomization and intervention
Randomization flowchart is shown in Fig. 1. The MASH cohort statistician
pre-randomized 70 participants to one of two groups and provided the list to the FIU
pharmacy prior to subject recruitment. Once potential participants were identified and
informed consent was obtained, the participant information was sent to the FIU
pharmacy to randomize the participants into either supplementation or placebo groups
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following the list provided by the statistician. To avoid observer bias, the vials were
blinded by completely covering the contents by the label prior to starting the study.
The pharmacist labelled the supplements with a group number and participant
identifier following the double-blinded assignment provided by the statistician.
Participants enrolled in the clinical trial were randomly assigned to receive a
daily oral supplementation of either one pill from NAC (100 mg/day) and one pill
from glycine (100 mg/day) by NOW FOODS or two placebo pills, which was
cellulose by Medisca. Supplements were dispensed during the baseline visit with 100
capsules in every bottle. Each participant received two bottles and was expected to
take one pill daily from each bottle. At the end of each visit the participants received
an incentive of $10.
Data collection/assessments
Data collection took place in the FIU Borinquen research clinic. Upon
consenting participants, demographics (age, gender, and ethnicity), CD4 cell count,
viral load, cocaine use, pre-supplementation GSH values and pre-supplementation
anthropometrics were obtained from the MASH cohort research charts. Participants
visited the clinic once a month; at each visit, blood was drawn for measurements of
oxidative stress including parameters of oxidative DNA damage and glutathione
status. Concentrations of GSH were assessed at baseline and at end of the clinical
trial. A pill count and current weight were obtained at each visit. At baseline and the
end of the clinical trial, bioelectrical impedance analysis (BIA) and 24-hour dietary
recalls were obtained.
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Blood collection and storage
A certified phlebotomist collected blood samples by peripheral venipuncture.
Three ml of venous blood was collected and aliquoted in two 1 ml EDTA tubes. The
samples were stored at –20 ° for approximately 20 minutes, then blood was
transported to the FIU laboratory on dry ice to be stored at – 80 °C until they were
analysed in batch.
Laboratory Determination of Total Glutathione and oxidized glutathione
Total glutathione and oxidized glutathione were measured in whole blood by
the Arbor Assay Glutathione Colorimetric, samples were analysed in triplicates.
Statistical Analysis
All statistical analyses were performed using SPSS (Version 21). Student t-test
was used to determine differences in mean values. Linear regression was used to
determine association of glutathione levels with other factors. Pearson correlation was
conducted to correlate measures of oxidative stress. For all analysis significance levels
was set at p< 0.05 level. Data was normally distributed (Fig 1).
Results
From the MASH cohort a total of 30 participants were randomly assigned to
either intervention or placebo group. Nineteen participants completed the threemonths clinical with eleven in the placebo group and eight in the intervention group.
The majority of the participants were males 66.6% (n=20), with mean age of 54.63±
6.305 (Table 1). Most of the participants were African American 73.3% (n=22). In
this population, 70% (n=21) were overweight.
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Table 2 shows baseline characteristics by group. In both groups there was more men,
84% in the intervention and 53% in the placebo. African Americans comprised the
majority in both groups, 66.7% (n=10) in the intervention and 80% (n=12) in the
placebo. There were no significant differences in demographic characteristics between
placebo and intervention group at baseline (Table 2).
In addition, there were no significant differences in levels of total GSH and
oxidized glutathione at baseline (Table 3). However, at the end of the study, we
observed decreased means of GSH in the intervention group. Total GSH decreased in
the intervention group by -36.98 µM and increased by 157.2 in the placebo group,
p=0.15. Oxidized glutathione decreased in the intervention group by -6.27 µM, and in
the placebo group increase by 1.1, p=0.75. Free glutathione decreased in the
intervention by -30.7 and increased in the placebo group by 156, p=0.19.
In table 4, we compared levels of GSSG and % GSSG pre- and postsupplementation on GSSG and %GSSG in only the participants who completed the
study (n=19), in the intervention and placebo group. We observed no significant
changes pre and post supplementation in GSSG and %GSSG in both groups.
However, the intervention group had a higher GSSG mean pre-supplementation
(81.5389±42.5) compared to post supplementation 75.26736± 41.67µM
In a linear regression model, using change in GSSG as our continuous
dependant variable (Table 5), there was a significant association between oxidative
DNA damage (SB/ALS) and change in GSSG (β= 0.541, 95% CI= 1.835, 17.859,
p=0.020). In the final model, group, cocaine use and pill adherence were included as
adjusting variables, as they were the only variables that showed some effect on the
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relationship of supplementation and changes on oxidative after three months of
supplementation.
Correlations between markers of oxidative stress:
At baseline, levels of GSH were significantly correlated with oxidative DNA
damage but not with BMI and body fat percentage. (Table 6) Both GSSG and percent
GSH were associated with oxidative DNA damage (r=-0.452, r= -0.422, p < 0.05,
respectively)
We further found in a two tailed Pearson correlation between GSSG and
oxidatively DNA damage (Table 6). ALS/SB were significantly correlated with
GSSG (r= -0.410, p < 0.05). ALS/SB + oxidized purines were significantly correlated
with GSSG (r= -0.452, p=0.012). ALS/SB + oxidized purines were sig correlated with
%GSSG (r=-0.4522, p<0.05)
Discussion
This randomized controlled clinical trial (RCT) presented decrease in levels of
glutathione (GSH and GSSG). Also, after three months of supplementation decreased
levels of GSSG as significantly associated with decreased levels of DNA damage
(AB/ALS). Our findings showed evidence that supplementation with NAC and
glycine compared to placebo has an effect on reduction of glutathione concentrations
among PLWH from the MASH cohort, but these changes did not reach significance.
Participants randomized into the intervention in this study were taking a daily dosage
of 100 mg of NAC and 100 mg glycine for a total of a twelve-week intervention. Our
results compare with those of Alfonos et. al,16 who supplemented a much higher dose
of 1,800 mg of NAC to people exposed to asbestos, using an RCT design, and found
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no effect on markers of oxidative stress. Our lack of significant results may be due to
a dose of supplementation that was too low to improve levels of GSH, compared with
what Alfonso et al. supplemented, however, other studies in PLWH have reported
effective doses similar to ours (0.81 mmol/kg/d of NAC and 1.33 mmol/kg/day of
glycine in HIV subjects). 11,17 Another factor to consider along with dosage, is the
treatment period of supplementation. It was established that NAC supplementation
from 12 -24 weeks was beneficial among bronchitis patients,18 which is similar to our
12- week intervention. However, a chronic infection such as HIV, with a chronic
treatment, generates higher oxidative stress than short-term infections, which may
explain the differences in results between these two studies. In addition, we have an
aging population, and oxidative stress is increased with aging.19
The most relevant study to compare our findings with is a study conducted by
the previous MASH cohort. 20 It was found that the average GSSG in PLWH was
217.6 µM and in this RCT levels of GSSG was 66.9 µM at baseline. While they
reported that %GSSG was 22.52, and in our study, it was 7.43 µM . The levels of
GSSG and %GSSG were much lower in our study compared to the findings from the
previous MASH cohort study, which indicate that the participants in the current study
may have less acute oxidative stress than those found in previous years, probably due
to advances in viral control and less toxic medications. Our cohort was selected
because adequate viral suppression and functional immune system, both factors that
may be contributing to less oxidative stress at baseline.
NAC supplementation has been found to be successful in improving GSH
deficiency, especially among individuals with infectious diseases.21 NAC acts as an
antioxidant22 as it replenishes levels of thiols resulting in improving the antioxidant
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capacity. In this regards there is a possibility that our supplementation regimen
improved the antioxidant capacity causing a specific effect on other tissues, as we
have found in our previous chapter that supplementation was very effective on the
level of oxidative DNA damage, including SB/ALS and SB/ALS+ oxidized purines.
Therefore, it is possible that supplementation was acting specifically as an antioxidant
on other tissues but not specifically in the enzymatic action of glutathione. It would be
helpful if we were able to measure and identify other oxidized metabolites.
Although our findings may not reach significance, yet, there was a positive change in
GSH levels. Our results, however, show decrease in GSSG in the intervention group
when we compare oxidation levels with the placebo group. (Figure 3), there was a
decrease by – 6.27 µM in the intervention group, while the placebo group increased
1.1 µM M after three months (Fig. 3). Moreover, % GSSG in the intervention group
slightly decreased more than percentage in the control group. (-0.7998±4.5,
0.1283±7.516, respectively) Hence, supplementation with NAC and glycine help
reduced levels of GSSG. The lack of significance may also be explained by the small
sample size.
In our population regardless of supplementation, there was a significant correlation
between GSSG and ALS/SB DNA damage p=0.012, which suggests that by reducing
oxidized glutathione, DNA damage may be reduced.
It has been previously established that oral supplementation of Nacetylcysteine (NAC), glutamine and glycine in PLWH increased plasma levels of
GSH and decreased inflammation.11,17,23 Findings from this study are not totally
parallel to the literature, as levels of GSH improved but not significantly. Oxidative
stress observed in these participants can be attributed to the HIV disease, obesity and
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aging, which are important factors that influence oxidative stress. 14,24 Most of our
subjects were older than 50 years obese and HIV infected.
There is evidence that supplementation with glycine and NAC was effective
among male PLWH 11as well as older PLWH.17 In our study, we expected to see
similar findings, we looked for gender differences but especially in the intervention
group, the majority of the subjects were males, which made findings sexual
differences difficult. Our population had an average age of 54 years, and when
dividing the population according to the CDC criteria25,26for aging, the majority of our
participants were in the aging group (83.3%, n=25), however, if we follow the IAS 26
criteria to consider aging, the majority are under the cut-off of aging (73.3%, n=22)
are younger than 60 years and only 26.7%(n=8) are aging. Therefore, if we categorize
our population according to the CDC our population falls at the beginning of the
aging process, however, according to the IAS criteria, our population is not suffering
the rigors of aging, including accelerated oxidative stress, yet.
In conclusion, results from this randomized double-blinded trial suggest that
supplementation, although demonstrating a protective effect measured by oxidized
glutathione, did not have a significant effect on glutathione status, a result that might
be affected by the small sample size, the dosage, and/or adequacy of glutathione
levels and its precursor amino-acids at baseline in this population. Therefore, the
strong relationship between a chronic HIV infection and levels of glutathione found
by other studies was not replicated in this study of supplementation, and, although the
changes in glutathione levels follow the direction of our hypothesis, they did not reach
significant differences between the two study groups.
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Strengths and Limitations:
Limitations to this study were sample size with a large dropout rate, as we had
only a small number of participants finishing the study, relatively short duration of the
clinical trial, and potentially low dosage of the supplements.16 The dosage
administered was lower than other studies that had populations with different
conditions, and that found that supplementation for a shorter time was beneficial11,17,18
and the specificity of the population after applying the inclusion/exclusion criteria,
which provides for low generalizability.

86

Screened from the MASH cohort at FIU Research
clinic in the Borinquen Health Center, Miami-Dade,
Florida.

75 were eligible
Excluded (n=45)
Not meeting inclusion criteria
Declined to participate
Lack to Adherence to medication
Not reachable
Others (Not English speakers)

30 participants

Intervention
Supplement group
n=15

Placebo n=15

Figure 1. Flowchart of Randomization
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Table 1: Baseline Demographics
Variable
Age

54.63± 6.305

Ethnicity %(n)
African American

73.3% (22)

Hispanic

13.3% (4)

White

13.3% (4)

Male

66.7% (20)

Female

33.3% (10)

Gender %(n)

BMI

26.13± 3.131

BMI categories %(n)
Underweight

3.3% (1)

Normal weight

20% (6)

Overweight

70% (21)

Obese

6.7 (2)

Data are means ± SD unless otherwise indicated
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Table 2: Characteristics of study participants by group
Variable

Intervention

Placebo

p-value

Age (years)

N=15
53.4±6.9

N=15
55.8±5.9

0.29

Gender (M) (%, n)

80 (12)

53 (8)

BMI (kg/m2)

26.92±2.3

25.35±3.7

African Americans
Hispanic
White

66.7 (10)
13.3 (2)
20 (3)

80 (12)
13.3 (2)
6.7 (1)

CD4+

546±298

577±230

.759

Viral Load

0.15±0.55

0.066±0.25

.590

Fat percentage

25.91±5.8

30.12±7.7

.104

CRP

8.15±16.2

6.02±7.197

.648

DNA damage (hOGG1)

4.6375 ±1.95

6.06±2.8

.118

DNA damage
(+hOGG1)

16.8±2.9

17.89 ±4

.407

Total Glutathione
(GSH)

962.6±361

902.98±237

.597

Oxidized Glutathione
(GSSG)

66.9±37.36

66.8995±38.09

.999

.173

Ethnicity(%, n)

Data are means ± SD unless otherwise indicated
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Table 3: Change Glutathione concentrations by groups
Intervention

Control

P-value

-36.9844±322

157.2491±240

0.15

GSSG

-6.27±42.57

1.11 ± 54.5

0.75

% GSH

-0.7998±4.5

0.1283±7.516

0.761

-30.7±350

156±249

0.191

Total GSH

Free GSH

All values are represented as mean ± SD. Data was analyzed using Student t-test. *Statistically
significant, p < 0.05
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Table 4: A comparison of GSSG and % GSSG in control and placebo groups at
baseline and end of study
Variable

N

Control

N

Intervention

p-value

Baseline GSSG

15

66.89 ± 38.096

15

66.91 ± 37.36

0.999

BL_% GSSG

15

7.2583 ± 3.53

15

7.60 ± 4.0472

0.805

V4 GSSG

11

70.42 ± 38.38

8

75.26 ± 41.67

0.797

V4 %GSSG

11

7.85 ± 5.37

8

6.97 ± 3.53

0.693

Data are means ± SD unless otherwise indicated
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Table 5: Linear Regression model of the effect of supplementation on changes in
GSSG from baseline to visit 4.
Variable

B

95% CI

β

t

p-value

Intervention

-0.726

[-43.73, 42.27]

-0.008

-0.036

0.972

Cocaine use

-22.595

[ -62.560,
17.59]

-.238

-1.147

.271

Pill adherence

26.435

[ -18.536,
71.407]

0.259

1.261

0.228

Baseline
SB/ALS

9.847

[1.835, 17.859]

0.541

2.636

0.020

..

*Statistically significant, P< 0.05, Dependent variable= change is GSSG
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Table 6: Pearson Correlation at Baseline

Total GSH

Total GSH
1

GSSG

% GSH

Free GSH

BMI

Fat%

GSSG

.246

1

% GSH

-.222

.829**

1

.993**

.126

-.331

1

BMI

.156

.072

-.075

.151

1

Fat %

.099

-.050

-.159

.107

-.069

1

-.343

-.452*

-.422*

-.294

-.038

.250

Free GSH

SB/ALS +
Oxidized Purines

** Significant at p< 0.01 level (2-tailed), *. Significant at p< 0.05 level (2-tailed), N=30
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Table 7: HIV aging Cut-off age according to the Disease Control and Prevention
(CDC) and the International AIDS Society (IAS):
Category
CDC

IAS

Percent (n)
< 50

16.7 (5)

>=50

83.3 (25)

< 60

73.3 (22)

>= 60

26.7(8)

Data represented as frequencies
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Normal QQ plot
150

GSSG baseline placebo

Predicted

GSSG visit 4 placebo
GSSG baseline Intervention

100

GSSG visit 4 Intervention
50

0
0

50

100

150

Actual
Fig. 1. Oxidized Glutathione (GSSG) Normality test

95

150

m=69.31

m=70.43

m=81.54

m=75.27

week 0

GSSG/mM

week 12
100

50

0

Intervention

Placebo

Fig. 2.Differences in oxidized glutathion (GSSG) pre/post supplementation in
placebo and intervention group Supplemenetation with NAC and Glycine decreases
GSSG by an average of 6.27 mM

Total GSH mM

200
150
100
50
0
-50
intervention

placebo

Fig. 3. Change in Total GSH after three months supplementation

Intervention -36.9±322 and placebo 157.2491± 240
Values Represented as means ± SD
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2

GSSG/mM

0
-2
-4
-6
-8
intervention

placebo

Fig. 4. Change in oxidized glutathione (GSSG) after three months supplementation

Intervention -6.27±42.57 and placebo 1.11 ± 54.5
values are represented as mean ± SD
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Fig. 5 Changes in oxidized glutathione (GSSG) after three months of
Supplementation

100

GSSG/mM

50
0
-50
-100
intervention

placebo

Fig. 1. Change in oxidized glutathione (GSSG) after three months supplementation
Supplementation decreased GSSG by -6.27 in the intervention group while the placebo had an increased 1.1
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Abbreviations:
GSH: Glutathione
GSSG: Oxidized Glutathione
PLWH: People Living With HIV
SB/ALS: Strand Breaks/Alkali-labile Sites
BMI: Body Mass Index
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Chapter VI: Cocaine Use, Inflammation, and adherence among PLWH from the
MASH cohort
Introduction
Inflammation is associated with many human diseases. A diet characterized by
antioxidant products is an emergent approach for dealing with inflammatory
responses in chronic diseases, as well as addressing some of the associated risk factors
such as obesity.1 Inflammation is part of the defense mechanisms of the human body;
it usually starts with the process of healing as a response to irritants and damaged
cells.2 Zican et al.3 reported, that despite highly effective antiretroviral therapy (ART),
people living with HIV (PLWH) face issues of chronic inflammation or immune
activation.
In this regard, high sensitivity C-reactive protein (hs-CRP) has become the
most widely utilized inflammation biomarker.4 Cocaine use is highly prevalent among
PLWH in Miami, where our study took place. We have found in our previous studies
that HIV infection is an important contributor to persistent oxidative stress, measured
by the rate of oxidized glutathione (GSSG) and reduced glutathione (GSH).5 GSH is a
tripeptide, formed by three amino-acids cysteine, glycine, and amino glutamine.6
Oxidative stress takes place when there is an imbalance between the formation of
reactive oxygen species (ROS) and the availability of internal and external antioxidant
defenses. PLWH, due to their chronic infection and its treatment, experience oxidative
imbalances. In addition, Dehal et al.7 and Reingold et al.4 have shown that cocaine use
in this population is associated not only with oxidative stress7 but also with
inflammation.5 Thus, our study of supplementation collected data on factors such as
cocaine use, markers of inflammation, and adherence to the supplement to determine
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the effects on oxidative stress. In addition, we have used these data to assess the
relationship among these factors, with and without the effects of supplementation.
Specifically, to reduce the impact of HIV-infection and its treatment on
oxidative stress, in our prior chapters we assessed the effect of N-acetylcysteine
(NAC) and glycine as an adjunct therapy, the clinical trial found that this combination
was effective to reduce oxidative stress as well as safe and well-tolerated in
agreement with previous trial.8 It has been noted, that oxidative stress is significantly
associated with morbidity and mortality among the PLWH but there is limited
information regarding the potential multiple mechanisms of action.9 This chapter
focuses on C-reactive protein as a marker of inflammation and the effect of
supplementation and cocaine use on inflammation. Cocaine use was equally
distributed between the intervention and placebo study groups. Therefore, we
explored the effect of NAC and glycine supplementation on inflammation and the role
of cocaine use in PLWH from the MASH cohort.10,11
Methods
Study Design
In a double-blinded randomized controlled clinical trial (RCT), we recruited
thirty PLWH from the Miami Adult Studies on HIV (MASH) cohort at Florida
International University (FIU) Research clinic at Borinquen Health Center, Miami,
Florida. This was a three-month intervention cohort from March 2018 –March 2019.
Subjects were randomly assigned to receive either NAC (100 mg/day) and glycine
(100 mg/day) or Placebo. The study was approved by the Florida International
University Intuitional Review Board.
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Subjects
Participants were eligible to participate if they were HIV-positive, free of comorbid diseases, on stable ART for more than six-months, have undetectable HIV
viral load (VL), CD4 cell count 500 or more, younger than 65 years old, BMI ≤ 30
kg/m2, English speaker, and not on nutrient supplementation for the past three
months.
Data Collection
During the clinical trial participants visited the clinic once a month for three
months with a total of four visits. Pre-supplementation data were collected from the
MASH cohort research charts, which included bioimpedance body composition
measures and biomarkers of inflammation (hs-CRP and TNF-α). At each visit a pill
count and adherence questionnaires were collected, weight was obtained, and blood
was drawn for outcome biomarkers. Cocaine use was obtained from the MASH
cohort reports, as some participants were characterized as cocaine users or non-users
according to the participants’ self-reported questionnaire, urine toxicology, and
cocaine blood biomarkers. We used the MASH cohort characterization for identifying
cocaine users and non-users.
High Sensitivity C-reactive protein
Data on inflammation was obtained from the MASH cohort documentation for
pre and post supplementation from the closest cohort visit. In the clinic, at each cohort
visit, fasting blood was drawn by a certified phlebotomist by peripheral venipuncture.
Blood samples were then transported to the HIV laboratory at FIU, where the samples
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were collected by LabCorp for analysis and provided the results to the MASH cohort
and documented.
Pill count and adherence
At the baseline visit pills were dispensed, with two bottles for each
participants for the entire study. Intervention group had two bottles one with NAC
pills and one with glycine pills, and the placebo group bottles both had placebo pills.
Participants were asked to bring their bottles at each visit for a pill count. Each bottle
had 100 pills, and each participant was expected to take one pill from each bottle
daily. One bottle was labeled with the letter A and one with the letter B. To assess
participants adherence, we calculated [# of pills given - # left] x100, an average for
both bottles and 80% was considered the cut-off for adherence. Participant were
considered adherent if they scored more or equal to 80% and non-adherent if they had
a score less than 80%.
Statistical Analysis:
Statistical analyses were performed using SPSS 20. The effects of the study
supplements were compared using an intent-to-treat analysis initially, and then
adjusted by rate of adherence to the supplements, cocaine use, and hs-CRP levels.
Descriptive statistics were used to characterize the study population at baseline, and to
compare by supplementation groups, cocaine use, hs-CRP, and pill adherence.
Student’s t-tests were used to assess mean differences in changes of CRP among
intervention and supplementation group, and to assess mean differences of biomarkers
of oxidative stress and inflammation among cocaine users and non-users. Linear
regression models were used to determine the relationship between CRP, fat %, and
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gender, and to assess the effect of supplementation on changes in inflammation from
baseline to the end of the study. Spearman rho and Pearson correlations were used to
determine the non-parametric and parametric correlations

Results
This clinical trial had a total of 30 participants, with 15 participants in each
group. Dropout rate was 37% for the total population, 47% (n=7) dropped out from
the intervention group, and 27% (n=4) dropped out from the control/placebo group.
Randomization achieved similar baseline demographic and biological
characteristics in both groups (Table1). Most of the participants were males 66.7% in
the intervention group and 33.3% in the placebo group, with a mean age of 54.63±6.3.
The majority of the participants were overweight 70% (n=21). African Americans
represented 73.3 %(n=22), Hispanic and White both represented 13.3% of the
population (n=4 each).
At baseline, demographic and biological characteristics were mostly similar by
cocaine use (Table 2). However, there was significant difference in CD4 among
cocaine users and non-users with cocaine users having lower CD4 cell counts than
non-users, p=0.046. Moreover, oxidized glutathione (GSSG) at baseline was higher
among cocaine users and was approaching significance, with a p=0.082.
The participants showed 68.4% adherence to the supplement regimen, where
intervention group was 75% adherent, while the placebo group was 63% adherent to
the pills (Table 3). The intent-to-treat analyses revealed that adherence with
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supplementation significantly decreased SB/ALS + oxidized purines after threemonth supplementation p=0.001 (Table 4). Pill adherence was significantly associated
with measures of oxidatively DNA damage, SB/ALS + oxidized purines, oxidized
purines only, and SB/ALS (p=0.001, p=0.020, p=0.029, respectively).
In a linear regression model, when looking on the effect of supplementation on
the change of hs-CRP, after three-month supplementation we observed significant
associations with gender p=0.011 and body fat % p=0.022, when adjusting for age
and BMI (Table 5). In the final model, supplementation was significantly associated
with gender p=0.005 and Fat % p=0.015, without adjusting for other variables.
Among the intervention group, change in hs-CRP was significantly associated with
GSSG p=0.019 and with BMI p=0.004 from baseline to end of clinical trial (Table 8).
In Table 7, we observed that cocaine use was approaching significance in the change
of BMI p=0.06 and SB/ALS p=0.054 after supplementation.
Discussion
In our double-blinded randomized clinical trial, levels of hs-CRP significantly
decreased after three-month of supplementation with NAC and Gly. This is in
agreement with findings from Sekhar et al,10 as they found that supplementation with
NAC and Gly significantly decreased levels of inflammation in PLWH. Another
similarity was that we observed decrease in body fat % after supplementation. An
important difference from Sekhar et al.10 was that we included both genders.
However, our findings also indicated that there was gender differences in improving
hs-CRP after three-month supplementation among males, similar to the findings from
Reingold et al.4 In another RCT, Alfonso et al. 12 supplemented NAC to people
exposed to asbestos and, different from our findings, found no evidence that
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supplementation reduced biomarkers of inflammation.13 These differences may be
explained by the differences in the population study, health conditions, sample size
and supplementation doses.
Compliance and adherence to the supplement in this small cohort was a
limitation of the study. We experienced high dropout rate, which was not expected,
but probably related to the frequent visits and low incentive compared with the
incentives offered by the parent grant, the MASH cohort. The baseline visit coincided
with the visit to the parent grant, but for the subsequent monthly visits we were
offering only $10 for pill counts, dispensation and blood draw. However, our study
led to significant findings on the relationship between adherence to the supplements
and oxidative DNA damage. In the intervention group 75% of the participants were
adherent to their supplements, and we found that those adherent with NAC and Gly
supplementation experienced reduction in inflammation. We observed significant hsCRP reduction after NAC and Glu supplementation, with significant decrease in body
fat % and BMI. In our study, CRP decreased among males, similar to the findings of
Reingold et al.4 The decrease in body fat % among PLWH may have been associated
with elevated hs-CRP levels.10
In the intervention group we observed that supplementation for three months
reduced GSSG, which was significantly associated with the reduction in the
biomarker of inflammation.
Cocaine use appears to have a significant effect on biological HIV marker. In
this clinical trial cocaine users represented 50% of the population in both groups.
Also, regardless of supplementation, CD4 cell count was significantly lower among
the cocaine users (p=0.045) at baseline. This may indicate that cocaine users, despite
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having undetectable viral load, their CD4 cell count has not recuperated to the levels
of non-users. Another observation among cocaine users is that oxidized glutathione
(GSSG) was higher with an average of 78.67 µM among users compared 55.13 µM to
non-users, p=0.082.
After three-month supplementation, we observed that BMI and SB/ALS
changed among cocaine users. BMI increased with an average of 0.47 kg/m2 among
cocaine users compared to an average decrease 0.5 kg/m2 in non-cocaine user. We
observed a decrease in SB/ALS in both groups, however, the average decrease in the
cocaine users was -11.3 % tail DNA compared to -14.4 % tail DNA in the cocaine
non-users, although did not reach significance.
Strengths and Limitations
The major limitation of our study remains small sample size for estimating our
experimental aims and high dropout rate. Our strength is that this is a double blinded
randomized clinical trial with a control group, which is the ideal design to determine
the effects of an intervention, that the length of the study was longer than other
relevant studies in the literature, and adequate to observe significant findings in the
outcome variables.
In conclusion, our findings show that NAC and Gly supplementation is
effective in reducing elevated levels of inflammation after three-month. Furthermore,
it decreased body fat %. Cocaine users experienced more oxidative damage and
higher inflammation than cocaine nonusers.
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Table 1: Baseline Characteristics of study participants by groups
Variable

Placebo
N=15
55.8±5.9

p-value

Age ( years)

Intervention
N=15
53.4±6.9

Gender (M) (%, n)

84 (12)

53 (8)

0.13

BMI ( kg/m2)

26.92±2.3

25.35±3.7

0.173

African Americans
Hispanic
White

66.7 (10)
13.3 (2)
20 (3)

80 (12)
13.3 (2)
6.7 (1)

0.322

CD4+

546±298

577±230

.759

Viral Load

0.15±0.55

0.066±0.25

.590

TNF-α

9.34±11.07

8.125±4.7

0.707

Fat percentage

25.91±5.8

30.12±7.7

.104

CRP

8.15±16.2

6.02±7.197

.648

DNA damage (-hOGG1)

4.6375 ±1.95

6.06±2.8

.118

DNA damage (+hOGG1)

16.8±2.9

17.89 ±4

.407

Total Glutathione (GSH)

962.6±361

902.98±237

.597

66.8995±38.09

.999

0.29

Ethnicity( %, n)

Oxidized Glutathione
66.9±37.36
(GSSG)
Data are means ± SD. P is considered significant at < 0.05
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Table 2: Baseline Characteristics of study participants by cocaine use
Variable

Non-users
N=15
55±7.09

p-value

Age ( years)

User
N=15
54.4±5.6

Gender (M) (%, n)

73.3 %(11)

60%(9)

0.456

BMI ( kg/m2)

26.92±2.3

26.31 ±3.03

0.347

African Americans
Hispanic

66.7 (10)
20 (3)

80 (12)
6.7 (1)
13.3 (2)

0.623

White

13.3 (2)

CD4+

465±208

659±2275

0.046*

Viral Load

0.214±0.57

0.0±0.

0.178

TNF-α

7±5.24

10±10.32

0.325

Fat percentage

28.91±6.3

27.13±6.318

0.500

CRP

6.90±6.9

7.27±16.51

0.937

SB/ALS

5.31 ±2.43

5.38±2.6

0.948

SB/ALS+ oxidized
purines

16.98±3.3

17.72 ±3.69

0.564

Total Glutathione (GSH)

998.5±261.7

867±332.7

0.239

55.13±31.36

0.082

0.733

Ethnicity( %, n)

Oxidized Glutathione
78.67±39.57
(GSSG)
Data are means ± SD.
*P is considered significant at < 0.05
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Table 3: Percentage of pill adherence according to the pill count and adherence
questionnaire in both groups
Group

Adherence
N= 13 (68.4%)

Non-adherence
N=6 (31.6%)

Control

63.6%
N=7
75%
N=6

36.3%
N=4
25%
N=2

Intervention
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Table 4: Linear Regression Models (1,2 and 3) on the effect of the Intervention and
Pill Adherence on Changes in oxidatively DNA damage from Baseline to 12-week
visit.
Variable Model 1

B

95% CI

β

t

p-value

Intervention

-3.652

[-6.131, -1.172]

-.472

-3.122

0.007*

Pill adherence

-4.860

[-7.494, -2.226]

-0.591

-3.912

0.001*

Dependent Variable: Difference SB/ALS + oxidized purines from baseline to Visit 4
*Statistically significant < 0.05
Variable Model 2

B

95% CI

β

t

p-value

Intervention

-2.369

[-5.789, 1.050]

-0.291

-1.469

0.161

Pill adherence

-4.413

[-8.045,-0.781]

-0.510

-2.576

0.020*

Dependent Variable: Oxidized purines only from baseline to Visit 4
*Statistically significant < 0.05
Variable Model 3

B

95% CI

β

t

p-value

Intervention

-1.863

[-4.952, 1.225]

-0.261

-1.279

0.219

Pill adherence

-3.721

[-7.001, -0.440]

-0.492

-2.404

0.029*

Dependent Variable: Difference SB/ALS
*Statistically significant < 0.05
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Table 5: Linear Regression Model on the effect of supplementation on inflammation
adjusted for gender, age, BMI, and Fat % on changes in CRP from baseline to end of
study.
Variable

B

95% CI

β

t

p-value

Intervention

1.984

[-8.216, 12.185]

.088

.420

.681

Gender

16.592

[4.462, 28.72]

0.654

2.955

0.011*

Age

0.346

[-0.452, 1.143]

.193

.936

.366

Baseline BMI

-0.352

[-1.993. 1.288]

-.096

-.464

.650

Baseline Fat %

0.827

[0.142, 1.153]

.581

2.608

.022*

Dependent Variable: change in CRP
*Statistically significant < 0.05
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Table 6: Linear Regression Model on the effect of supplementation, gender and Fat
% on changes on CRP from baseline to end of study.
Variable

B

95% CI

β

t

p-value

Intervention

3.346

[-6.268, 12.961]

0.148

0.742

0.470

Gender

17.717

[6.109, 29.325]

0.698

3.253

0.005

Baseline Fat %

0.846

[0.187, 1.506]

0.595

2.735

0.015

Dependent Variable: change in CRP
*Statistically significant < 0.05
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Table 7: Change in BMI and SB/ALS from baseline to week 12 in cocaine users
compared with non-users.
Variable

Cocaine users
n=9

Cocaine non-users
n=10

Change in BMI

0.47+1.42

-0.5400±0.685

Change in SB/ALS

-11.3147±3.475

-14.4734±3.186

Data are means ± SD. P is considered significant at < 0.05
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p-value
0.060

0.054

Table 8: Linear Regression Model on the effect of supplementation, GSSG, BMI, and
age on changes in CRP from baseline to end of study among the intervention group.
Variable

B

95% CI

β

t

p-value

GSSG

-2.659

[-4.597, -0.721]

-0.732

-3.809

0.019*

Baseline BMI

-5.762

[-11.282, -0.241]

-0.791

-2.898

0.044*

Age

-1.040

[-2.581, 0.502]

-0.511

-1.873

0.134

Dependent Variable: change in CRP
*Statistically significant < 0.05
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Chapter VII: FUTURE RESEARCH
Our findings from this double-blinded randomized clinical trial indicate that NAC
and glycine supplementation showed promising results. Supplementation was effective in
reducing oxidative DNA damage. This is the first study to assess the effect of oral NAC
and glycine on oxidative DNA damage using the comet assay among PLWH. The sample
size was small and the dropout rate was high. A greater understanding is needed with
regards of the role of NAC and glycine separately on oxidative DNA damage. To observe
the effect of supplementation on GSH and GSSG a clinical trial with a higher dosage may
be effective in significantly reducing levels of GSH.
Further research is needed to be conducted with a higher supplementation does,
larger sample size, a factorial design, and to consider measuring levels of cysteine and
glycine pre and post supplementation.
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ADULT CONSENT TO PARTICIPATE IN A RESEARCH STUDY
Three-month nutritional supplementation to reduce oxidative stress in people living with HIV
(PLWH)
PURPOSE OF THE STUDY
You are being asked to be in a research study. The purpose of this study is to assess the effect of
nutritional supplementation with a combination of the antioxidants N-Acetyl Cysteine (1,000
mg/day) and glycine (1000 mg /day) or a placebo on markers of oxidative stress and inflammation
among PLWH.
NUMBER OF STUDY PARTICIPANTS
If you decide to be in this study, you will be one of 70 people screened for this research study.
DURATION OF THE STUDY
Your participation will require participation for 3 months and you will be asked to visit the clinic 4
times for 3 months: at baseline, beginning of the second and third month, and at the end of the third
month. You will be placed at random (like the flip of a coin) in either the control (comparison) group
or the intervention group. You will be required to come to the research clinic 4 times: once for the
screening, baseline visit and first dispensation, and 3 more visits for follow-up. Your first visit will
either coincide with your MASH clinic visit as part of the MASH study or a separate baseline visit.
Visits 2, 3, and 4 are additional to the one in the MASH cohort study. In each visit, the following
activities will take place:
Visit 1: Recruitment, consenting, screening, baseline and dispensations (45 minutes for
questionnaires, urine sample and finger prick or blood-draw)
Visit 2: Beginning of the second month, questionnaire, urine sample, finger prick or blood-draw,
adverse events questionnaire and pill count.
Visit 3: Beginning of the second month, questionnaire, urine sample, finger prick or blood-draw,
adverse events questionnaire and pill count.
Visit 4: End of the third month, questionnaire, urine sample, finger prick, blood drawing, adverse
events questionnaire and pill count
PROCEDURES
If you agree to be in the study, you will be placed in either the control or intervention group at
random (like the toss of a coin). For both groups you will be asked to do the following:
1. When you come for your appointment for the MASH study, you will be asked if you would like
to participate in this study, explain the study and consent you if you are willing to participate. We
will ask you if you allow us to access your medical and laboratory records maintained in the
MASH cohort under your research ID at the end of this consent form.
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2. With your permission, any remaining frozen blood will be used for future research.
3. The baseline visit for this study will occur after the screening and consenting, which might be at
the same time you come to the MASH study visit. At the baseline visit, and at the beginning of
the second and third month in the study, your visits will include finger prick or blood-draw
depending on participant preference and blood flow, pill dispensation, urine sample for measures
of oxidative stress, and anthropometric measurements (weight, waist circumference). You will be
asked to bring your pill bottle with you to count the leftover pills. These visits will last
approximately 45 minutes.
4. At the end of this study, the end of the third month, you will come for weight, waist
circumference, 24-hour recall, blood drawing and a urine sample. You will be asked to bring
your pill bottle with you. This visit should take 30 min.
5. You will be contacted once weekly by telephone to remind you about your pills, follow-up with
your health, and ask about side effects.
RISKS AND/OR DISCOMFORTS
The following risks may be associated with your participation in this study: Blood drawing include:
discomfort with needle, a possibility of bruising, and fainting. Adverse effects from the supplements
could be: upset stomach, fatigue, or skin rash, although these are rare occurrences.
For women only: If you are pregnant or intending to get pregnant, you will be excluded from the
study because you will need prenatal vitamins. If you become pregnant during the study you will be
terminated and recommended to obtain adequate supplementation.
BENEFITS
The following benefits may be associated with your participation in this study:
1. Nutrition consultations.
2. Opportunity to find out more about yourself and keep track of your health.
3. Chance to contribute to the field of science and HIV treatment.
4. Those in the intervention group may benefit from receiving a nutritional supplement that is
an antioxidant.
INCIDENTAL FINDINGS
Although the primary aim of this Nutritional Supplementation Clinical Trial is to improve the
antioxidant defense system and prevent and/or delay the onset of inflammation, if you develop any
symptoms related to your supplementation during the study, we will refer you to your primary care
physician with your permission, stop the supplementation immediately, and unblind your
supplements.
ALTERNATIVES
You may receive nutritional supplementation similar to the one provided in this study without
prescription, as this combination is considered an over-the-counter antioxidant. Any significant new
findings developed during the course of the research which may relate to your willingness to
continue your participation will be provided to you.

CONFIDENTIALITY
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The records of this study will be kept private and will be protected to the fullest extent provided by
law. The MASH cohort has a Certificate of Confidentiality that will be extended to this study. To
help us protect your privacy, we have a Certificate of Confidentiality from the National Institutes of
Health (NIH). With this Certificate, we can’t be forced by a court order or subpoena to disclose
information that could identify you in any civil, criminal, administrative, legislative or other
proceedings. There are circumstances where the Certificate doesn’t protect against disclosure of your
personally identifiable information:
when the US government is inspecting or evaluating federally-funded studies
when information must be disclosed to meet FDA requirements
if you give someone written permission to receive research information or you voluntarily
disclose your study information
if the researcher reports that you threatened to harm yourself or others
in cases of child abuse reported by the researcher
if the investigator reports cases of contagious disease (such as HIV) to the state
In any sort of report, we might publish, we will not include any information that will make it possible
to identify a subject. Research records will be stored securely and only the research team will have
access to the records. However, your records may be reviewed for audit purposes by authorized
University or other agents who will be bound by the same provisions of confidentiality.
The U.S. Department of Health and Human Services (DHHS) may request to review and obtain
copies of your records. The Food and Drug Administration (FDA) may request to review and obtain
copies of your records.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by
US Law. This web site will not include information that can identify you. At most, the web site will
include a summary of the results. You can search this website at any time.
COMPENSATION & COSTS
At each of the four study visits you will receive a payment of $10 for a total of $40. You will not be
responsible for any costs to participate in this study.
MEDICAL TREATMENT
Routinely, FIU, its agents, or its employees do not compensate for or provide free care for human
subjects in the event that any injury results from participation in a research project. If you become ill
or injured as a direct result of participating in this study, contact your regular medical provider. If
you have insurance, your insurance company may or may not pay for these costs. If you do not have
insurance, or if your insurance company refuses to pay, you will be billed. Funds to compensate for
pain, expenses, lost wages and other damages caused by injury are not routinely available.
STORED BLOOD
With your consent, some of your blood that is left over, after all necessary study testing is done, will
be stored. Your blood will not be identified by your name or by other personal information but would
instead be identified by a number that could later be linked to other information that was collected as
part of the study. This blood will be used for future HIV and antioxidants related research that will be
approved by the Florida International University Institutional Review Board and the United States
National Institutes of Health, which is sponsoring this study. Please decide if you agree to have some
of your blood stored for this reason; you will indicate your decision on the last page of this consent
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form. You may withdraw your consent for the use of specimens at any time. If you decide in the
future that you do not want your leftover blood to be used for research, study personnel will notify
the Laboratory Manager, who will have the specimens discarded.
RIGHT TO DECLINE OR WITHDRAW
Your participation in this study is voluntary. You are free to participate in the study or withdraw
your consent at any time during the study. Your withdrawal or lack of participation will not affect
any benefits to which you are otherwise entitled. The investigator reserves the right to remove you
without your consent at such time that they feel it is in the best interest.
RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this research
study you may contact Adriana Campa at Florida International University AHC 5- 328, 305-3482871, campaa@fiu.edu.
IRB CONTACT INFORMATION
If you would like to talk with someone about your rights of being a subject in this research study or
about ethical issues with this research study, you may contact the FIU Office of Research Integrity by
phone at 305-348-2494 or by email at ori@fiu.edu.
PARTICIPANT AGREEMENT
I have read the information in this consent form and agree to participate in this study. I have had a
chance to ask any questions I have about this study, and they have been answered for me. I
understand that I will be given a copy of this form for my records.
☐ I consent to the release and sharing of medical and laboratory information between the records of
the MASH cohort and this study.
______
Initials
☐ Check here if you agree to allow extra blood to be stored for future HIV related research.
☐ Check here if you DO NOT agree to allow extra blood to be stored for future HIV related
research.
________________________________
Signature of Participant

__________________
Date

________________________________
Printed Name of Participant
________________________________
Signature of Person Obtaining Consent

__________________
Date

________________________________
Printed Name of Person Obtaining Consent
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